

FOR OFFICIAL USE ONLY

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office54166  
SEARCH REQUEST FORM

Examiner # (Mandatory): 73510

Requester's Full Name: Chris. T. Le

Art Unit 1651

Location (Bldg/Room#): 11 B09

Phone (circle 305 306 308) 7114

Serial Number: 09/890,416

Results Format Preferred (circle): PAPER DISK E-MAIL

Title of Invention

Inventors (please provide full names): Drugs, foods, oral cumps containing  
stilbene-type compounds.

Earliest Priority Date: 1/29/99

Keywords (include any known synonyms registry numbers, explanation of initialisms)

RECEIVED  
NOV - 1 2001  
(STIC)  
Search Topic:

Please write detailed statement of the search topic, and the concept of the invention. Describe as specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples of relevant citations, authors, etc., if known. You may include a copy of the abstract and the broadcast or most relevant claim(s).

Please search the compound of claim 1 <sup>attached</sup> for treating  
bone loss (e.g. osteoporosis) or for treating  
hypertension, especially.

-Thanks

## STAFF USE ONLY

Searcher: S. J. [unclear]

Searcher Phone #: 308-4499

Searcher Location:

Date Picked Up:

Date Completed: 11/19/01

Clerical Prep Time:

Terminal Time:

Number of Databases:

## Type of Search

\_\_\_ N.A. Sequence

\_\_\_ A.A. Sequence

\_\_\_ Structure (#)

\_\_\_ Bibliographic

\_\_\_ Litigation I

\_\_\_ Fulltext

\_\_\_ Procurement

\_\_\_ Other

## Vendors (include cost where applicable)

\_\_\_ STN

\_\_\_ Questel/Orbit

\_\_\_ Lexis/Nexis

\_\_\_ WWW/Internet

\_\_\_ In-house sequence systems (list)

\_\_\_ Dialog

\_\_\_ Dr. Link

\_\_\_ Westlaw

\_\_\_ Other (specify)

=> fil hcaplus  
 FILE 'HCAPLUS' ENTERED AT 09:50:53 ON 19 NOV 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 Nov 2001 VOL 135 ISS 22  
 FILE LAST UPDATED: 18 Nov 2001 (20011118/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=>

=>

=> d stat que 115  
 L1 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC I  
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L7 65281 SEA FILE=REGISTRY SSS FUL L1  
 L11 40827 SEA FILE=HCAPLUS ABB=ON PLU=ON L7  
 L12 99 SEA FILE=HCAPLUS ABB=ON PLU=ON L11(L) (BONE(2A) (LOSS OR RESORP?) OR ?OSTEOPO? OR ?HYPERTENS? OR (BLD OR BLOOD) (W) PRESSURE)  
 L14 978 SEA FILE=HCAPLUS ABB=ON PLU=ON L7(L) (?MEDIC? OR ?PHARM? OR ?DRUG? OR ?THERP?)

L15 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND L12

=> d ibib abs hitrn l15 1-10

L15 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2001:555210 HCAPLUS  
 DOCUMENT NUMBER: 135:142233  
 TITLE: Pharmaceutical compositions containing estrogen agonist/antagonist and statins for treatment of osteoporosis and/or for lowering blood cholesterol  
 INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001206845	A2	20010731	JP 2001-15626	20010124
EP 1123717	A2	20010816	EP 2001-1300527	20010122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:  
 US 2000-188923 P 20000126  
 US 2000-205327 P 20000421

OTHER SOURCE(S): MARPAT 135:142233

AB The invention provides a compn. contg. an estrogen agonist/antagonist, and a statin deriv for treatment of osteoporosis and/or for lowering blood cholesterol. The antiosteoporotic effect of (-)-cis-6-phenyl-5-[4-(2-pyrrolidine-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol (PPTN) in ovary-excised rats were examd.

IT 10540-29-1, Tamoxifen 68047-06-3, 4-Hydroxytamoxifen  
 89778-26-7, Toremifene 116057-75-1, Idoxifene  
 155701-61-4, GW5638 195611-82-6, GW7604

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. contg. estrogen agonist/antagonist and statins for treatment of **osteoporosis** and/or for lowering blood cholesterol)

L15 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2001:541600 HCAPLUS  
 DOCUMENT NUMBER: 135:117261  
 TITLE: Method using estrogen agonists/antagonists for reducing morbidity and the risk of mortality from cardiovascular disease, breast cancer, and osteoporosis  
 INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Eur. Pat. Appl., 37 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1118323	A2	20010725	EP 2001-1300159	20010109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001226265	A2	20010821	JP 2001-5300	20010112
PRIORITY APPLN. INFO.:			US 2000-175663	P 20000112
OTHER SOURCE(S): MARPAT 135:117261				

AB The invention discloses methods, pharmaceutical compns., and kits useful in reducing cardiovascular morbidity and the risk of mortality in men and post-menopausal women and morbidity and the risk of mortality in post-menopausal women from the combined redn. of breast cancer, osteoporosis and cardiovascular disease by the administration of estrogen agonists/antagonists. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration.

IT **82413-20-5 82413-20-5D**, isomers, N-oxides, esters, and **prodrug** derivs. **83647-31-8 83647-31-8D**, isomers, N-oxides, esters, and **prodrug** derivs. **83647-33-0 83647-33-0D**, isomers, N-oxides, esters, and **prodrug** derivs. **83647-34-1 83647-34-1D**, isomers, N-oxides, esters, and **prodrug** derivs. **103199-13-9 103199-13-9D**, isomers, N-oxides, esters, and **prodrug** derivs. **170928-99-1 170928-99-1D**, isomers, N-oxides, esters, and **prodrug** derivs.

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and **osteoporosis**)

L15 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:778967 HCAPLUS

DOCUMENT NUMBER: 132:231295

TITLE: Selective oestrogen receptor modulation: molecular pharmacology for the millennium

AUTHOR(S): Levenson, A. S.; Jordan, V. C.

CORPORATE SOURCE: Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL, 60611, USA

SOURCE: Eur. J. Cancer (1999), 35(12), 1628-1639

PUBLISHER: CODEN: EJCAEL; ISSN: 0959-8049

DOCUMENT TYPE: Elsevier Science Ltd.

LANGUAGE: Journal; General Review

English

AB A review with 34 refs. Knowledge of the mechanism of action and pharmacol. of tamoxifen and raloxifene, for the prevention of breast cancer and osteoporosis resp., has opened the door for the discovery of multifunctional medicines. There is now the potential to prevent osteoporosis, coronary heart disease, breast and endometrial cancer in postmenopausal women with elevated risk factors.

IT **10540-29-1**, Tamoxifen

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(selective estrogen receptor modulation and mol. **pharmacol.** in relation to breast cancer treatment and **osteoporosis**)

prevention and treatment in postmenopausal women)

REFERENCE COUNT: 135

REFERENCE(S): (1) Aronica, S; Mol Endocrinol 1993, V7, P743 HCAPLUS  
(2) Assikis, V; Eur J Cancer 1996, V32A, P1464 HCAPLUS  
(4) Beato, M; Endocrine Rev 1996, V17, P587 HCAPLUS  
(6) Belleau, B; J Med Chem 1964, V7, P776 HCAPLUS  
(7) Berry, M; EMBO J 1990, V9, P2811 HCAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:9719 HCAPLUS

DOCUMENT NUMBER: 130:61616

TITLE: A combined pharmaceutical preparation comprising  
parathyroid hormone and a bone resorption inhibitor

INVENTOR(S): Dietrich, John; Ljunghall, Sverker; Sjogren, Sven

PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857656	A1	19981223	WO 1998-SE1095	19980608
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9879458	A1	19990104	AU 1998-79458	19980608
ZA 9804947	A	19990104	ZA 1998-4947	19980608
EP 1001802	A1	20000524	EP 1998-929965	19980608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6284730	B1	20010904	US 1998-125247	19980814
PRIORITY APPLN. INFO.:			SE 1997-2401	A 19970619
			WO 1998-SE1095	W 19980608
AB	The invention relates to a combined pharmaceutical prepn. comprising parathyroid hormone and a bone resorption inhibitor, said prepn. being adapted for (a) the administration of parathyroid hormone (PTH) during a period of approx. 6 to 24 mo; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approx. 12 to 36 mo. An example was given showing an enhanced effect on bone mineral d. with sequential administration of PTH and the bisphosphonate alendronate.			
IT	10540-29-1, Tamoxifen 82413-20-5, Droloxifene 89778-26-7, Toremifene 116057-75-1, Idoxifene			
RL:	MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(estrogen modulator; combined pharmaceutical prepn. comprising parathyroid hormone and a bone resorption inhibitor)			
REFERENCE COUNT:	3			
REFERENCE(S):	(1) Flora, L; US 4822609 A 1989 HCAPLUS			

(2) Pfizer Inc; EP 0792639 A1 1997 HCAPLUS  
 (3) Steven, W; US 5118667 A 1992 HCAPLUS

L15 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1997:589150 HCAPLUS  
 DOCUMENT NUMBER: 127:239133  
 TITLE: Pharmaceutical compositions containing combination of  
 droloxifene and progestins for the treatment of  
 osteoporosis  
 INVENTOR(S): Maclean, David B.; Thompson, David D.  
 PATENT ASSIGNEE(S): Pfizer Inc., USA  
 SOURCE: Eur. Pat. Appl., 9 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 791356	A1	19970827	EP 1997-301173	19970221
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09315977	A2	19971209	JP 1997-39073	19970224
CA 2198574	AA	19970828	CA 1997-2198574	19970226
AU 9714967	A1	19970904	AU 1997-14967	19970227
AU 712656	B2	19991111		
ZA 9701718	A	19980827	ZA 1997-1718	19970227
US 6057309	A	20000502	US 1998-193265	19981116
PRIORITY APPLN. INFO.:			US 1996-12400	P 19960228
			US 1997-803710	B1 19970221

OTHER SOURCE(S): MARPAT 127:239133  
 AB Pharmaceutical compns. comprising an effective amt. of droloxifene  
 (Markush structure given) or a pharmaceutically acceptable salt thereof  
 together with a progestin are useful for inhibiting bone loss. Tablets  
 contg. the above active ingredients 0.25-100, microcryst. cellulose  
 200-650, silicon dioxide 10-650, and stearic acid 5-15 mg each were prepd.  
 The efficacy of the combination in treatment of a model of post-menopausal  
 osteoporosis in rats is shown.  
 IT 82413-20-5 97752-20-0, Droloxifene citrate  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. contg. combination of droloxifene and  
 progestins for treatment of osteoporosis)

L15 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1996:763169 HCAPLUS  
 DOCUMENT NUMBER: 126:42532  
 TITLE: Pharmacodynamic observation of ipriflavone as a bone  
 resorption inhibitor  
 AUTHOR(S): Wu, Jingsheng; Liu, Zheng; Xue, Shuying; Chen, Siwei;  
 Wang, Minwei  
 CORPORATE SOURCE: Dep. of Pharmacology, Shenyang Pharmaceutical Univ.,  
 Shenyang, 110015, Peop. Rep. China  
 SOURCE: Zhongguo Yiyao Gongye Zazhi (1996), 27(7), 307-310  
 CODEN: ZYGZEA; ISSN: 1001-8255  
 PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Chinese  
 AB Ipriflavone increased the bone d. that was decreased by prednisolone and

the capability of femoral bone against mechanic collision. It also increased serum phosphorus and calcitonin levels in combination with diethylstilbestrol.

IT 56-53-1, Diethylstilbestrol

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**pharmacodynamic** observation of ipriflavone as a **bone resorption** inhibitor)

L15 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:483293 HCAPLUS

DOCUMENT NUMBER: 125:158592

TITLE: Zinc-calcium interaction in heparin-induced osteoporotic rabbit plasma

AUTHOR(S): Turan, B.; Delibasi, E.; Sinav, B.; Akkas, N.

CORPORATE SOURCE: Fac. Med., Ankara Univ., Ankara, 06100, Turk.

SOURCE: Trace Elem. Electrolytes (1996), 13(3), 138-142

CODEN: TEELEO; ISSN: 0946-2104

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heparin (Liquemin) i.p. (1000 IU/kg/day) was administered to rabbits for 8 wk (group A). Animals of group B were injected calcitonin (100 IU/kg/day) in addn. to heparin (1000 IU/kg/day). Animals in group C were medicated like group B and 2 mg/kg/day tamoxifen (Nolvadex) was orally added to their diet. Heparin (A) and heparin + calcitonin (B) treatment caused an increase and a decrease in the blood plasma Ca and Zn levels, resp., whereas addnl. tamoxifen (C) treatment did not alter the Ca level, but the Zn level was still lower than the control. Plasma mineral contents (Na, K, Cl) except P decreased. The estrogen and globulin levels in blood serum increased, whereas the serum albumin and alk. phosphatase levels decreased. Some alterations in plasma biochem. parameters of heparin-induced osteoporotic animals were obsd. and some of these alterations were reversed by tamoxifen treatment.

IT 10540-29-1, Tamoxifen

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(zinc-calcium interaction in heparin-induced **osteoporosis** response to therapeutic **drugs**)

L15 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1984:132789 HCAPLUS

DOCUMENT NUMBER: 100:132789

TITLE: Clomiphene protects against osteoporosis in the mature ovariectomized rat

AUTHOR(S): Beall, Paula T.; Misra, Lalith K.; Young, Ronald L.;

CORPORATE SOURCE: Spjut, Harlan J.; Evans, Harlan J.; LeBlanc, Adrian  
Dep. Physiol., Baylor Coll. Med., Houston, TX, 77030, USA

SOURCE: Calcif. Tissue Int. (1984), 36(1), 123-5

CODEN: CTINDZ; ISSN: 0171-967X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Clomid (clomiphene citrate) [50-41-9], a mixed estrogen agonist-antagonist, protects mature ovariectomized breeder rats from changes in total body Ca and from deterioration of femur structure. Over 6 mo, mature ovariectomized rats took up Ca at the rate of 0.7 mg/day, whereas normal controls gained 2.5 mg/day. Injections of clomiphene kept ovariectomized rats in pos. Ca balance at 2.0 mg/day. Redns. in total femur Ca content, cortical thickness, and visible trabeculae of femurs in ovariectomized animals were prevented by chronic clomiphene

administration. This suggested a possible new line of investigation of the use of antiestrogenic **drugs** as therapeutic agents for hormone-dependent **osteoporosis** in animals and humans.

IT 50-41-9

RL: BIOL (Biological study)

(**osteoporosis** inhibition by, after ovariectomy, calcium metab. in relation to)

L15 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1980:561250 HCAPLUS

DOCUMENT NUMBER: 93:161250

TITLE: Effect of an anion transport inhibitor on blood-brain barrier lesions during acute hypertension. Possible prevention of transendothelial vesicular transport

AUTHOR(S):

CORPORATE SOURCE:

Hardebo, Jan Erik; Johansson, Barbro B.  
Dep. Histol. Neurol., Univ. Lund, Lund, S-223 62, Swed.

SOURCE:

Acta Neuropathol. (1980), 51(1), 33-8

DOCUMENT TYPE:


CODEN: ANPTAL; ISSN: 0001-6322

LANGUAGE:

Journal

GI

English



I

AB SITS (I) [51023-76-8] prevented leakage across the blood-brain barrier (BBB) into the brain parenchyma following a **hypertensive** insult induced by a local increase of the intraluminal pressure in anesthetized rats and by i.v. administration of adrenaline or bicuculline in conscious unrestrained animals. Since SITS increased cerebral blood flow the protection cannot be explained by a constrictor action on the cerebral vessels. SITS is a **drug** with complex action on the cell membrane including an inhibitory effect on anion transport mechanisms and on some cyclic AMP-mediated processes. It is possible that the protection of the BBB obsd. in the present study is related to a decrease in cyclic AMP, but a membrane-stabilizing effect can at present not be excluded.

IT 51023-76-8

RL: BIOL (Biological study)

(blood-brain barrier lesions during acute **hypertension** prevention by)

L15 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1980:437284 HCAPLUS


DOCUMENT NUMBER: 93:37284

TITLE: Longistylane C, antibiotic isolated from Lonchocarpus longistyllus. Preliminary results of its pharmacological properties

AUTHOR(S):

Cotias, Claudio Tenorio; Francisco de Mello, Jose;  
Pinto, Karlina de Valesio; Goncalves de Lima, Oswaldo

CORPORATE SOURCE: Inst. Antibiot., Recife, Brazil  
 SOURCE: Rev. Quim. Ind. (Rio de Janeiro) (1979), 48(564),  
 12-15  
 CODEN: RQIRAI; ISSN: 0370-694X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Portuguese  
 GI



AB Longistylin C (I) [64125-60-6] appeared to have no significant effects on the parameters tested (**blood pressure**, cardiac frequency, smooth muscle, analgesia, inflammation, etc.) in lab. animals.  
 IT 64125-60-6  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacol. of)

=> select hit rn 115 1-10  
 E1 THROUGH E17 ASSIGNED

=> fil reg  
 FILE 'REGISTRY' ENTERED AT 09:52:47 ON 19 NOV 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5  
 DICTIONARY FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
 =>  
 => d his 116

(FILE 'HCAPLUS' ENTERED AT 09:50:53 ON 19 NOV 2001)

SELECT HIT RN L15 1-10


L16 FILE 'REGISTRY' ENTERED AT 09:52:47 ON 19 NOV 2001  
17 S E1-E17

=>  
=>

=> d ide can l16 tot

L16 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2001 ACS  
RN 195611-82-6 REGISTRY  
CN 2-Propenoic acid, 3-[4-[(1E)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 2-Propenoic acid, 3-[4-[1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl]-, (E,E)-  
OTHER NAMES:  
CN GW 7604  
FS STEREOSEARCH  
MF C25 H22 O3  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, TOXLIT

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7 REFERENCES IN FILE CA (1967 TO DATE)  
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:235901  
REFERENCE 2: 135:142233  
REFERENCE 3: 134:290091  
REFERENCE 4: 132:59356  
REFERENCE 5: 132:58844  
REFERENCE 6: 130:163193

REFERENCE 7: 127:243213

L16 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2001 ACS  
RN 170828-00 1 REGISTRY

RN 170928-99-1 REGISTRY

Phenol, 3-[ (1E)-1-[4-[2-[ethyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-[ethyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-


FS STEREOSEARCH

MF C33 H35 N O2

SR	CA
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
4 REFERENCES IN FILE GABUS (1967- )

4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:102844

REFERENCE 3: 129:23441

REFERENCE 4: 123:330040

L16 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2001 ACS  
RN 155701 61 4 REGISTRY

RN 155701-61-4 REGISTRY

CN 2-Propenoic acid, 3-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenyl]-, (2E)- (9CI)  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

OTHER NAMES:  
CN 2-Propenoic acid, 3-[4-(1,2-diphenyl-1-butenyl)phenyl]-, (E,Z)-

OTHER NAMES:

CN GW 5638

FS STEREOSEARCH


MF C25 H22 O2

CI	COM
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

SR CA

LC STN Files: BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, DRUGNL,  
DRUGUPDATES, EMBASE, MEDLINE, PHAR, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1967 TO DATE)  
16 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:235901  
REFERENCE 2: 135:142233  
REFERENCE 3: 135:132470  
REFERENCE 4: 135:102118  
REFERENCE 5: 135:28547  
REFERENCE 6: 135:28546  
REFERENCE 7: 134:305328  
REFERENCE 8: 134:95501  
REFERENCE 9: 132:40534  
REFERENCE 10: 131:282013

L16 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 116057-75-1 REGISTRY

CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pyrrolidine, 1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]-, (E)-

OTHER NAMES:

CN CB 7432

CN Idoxifene

CN SB 223030


FS STEREOSEARCH

MF C28 H30 I N O

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL  
(\*File contains numerically searchable property data)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

99 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 100 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:205530  
 REFERENCE 2: 135:205490  
 REFERENCE 3: 135:142233  
 REFERENCE 4: 135:132470  
 REFERENCE 5: 135:116436  
 REFERENCE 6: 135:86677  
 REFERENCE 7: 135:82051  
 REFERENCE 8: 135:71210  
 REFERENCE 9: 135:71043  
 REFERENCE 10: 135:55767

L16 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 103199-13-9 REGISTRY


CN Phenol, 3-[(1E)-1-[4-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-

FS STEREOSEARCH  
 MF C32 H33 N O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:102844

REFERENCE 3: 129:23441

REFERENCE 4: 123:330040

REFERENCE 5: 105:42468

L16 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 97752-20-0 REGISTRY

CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt)

OTHER NAMES:

CN Droloxifene citrate

FS STEREOSEARCH

MF C26 H29 N O2 . C6 H8 O7

SR Commission of European Communities

LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, DRUGPAT, DRUGUPDATES, MRCK\*, PROMT, RTECS\*, SYNTHLINE, TOXLIT, ULIDAT, USAN, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*


(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 82413-20-5

CMF C26 H29 N O2


Double bond geometry as shown.



CM 2

CRN 77-92-9

CMF C6 H8 O7



27 REFERENCES IN FILE CA (1967 TO DATE)  
 27 REFERENCES IN FILE CAPLUS (1967 TO DATE)

- REFERENCE 1: 134:189063  
 REFERENCE 2: 132:102844  
 REFERENCE 3: 131:106847  
 REFERENCE 4: 130:173031  
 REFERENCE 5: 130:47499  
 REFERENCE 6: 129:298396  
 REFERENCE 7: 129:166227  
 REFERENCE 8: 129:23441  
 REFERENCE 9: 128:303587  
 REFERENCE 10: 128:248582


L16 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2001 ACS  
 RN 89778-26-7 REGISTRY  
 CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-,  
(Z)-

## OTHER NAMES:

CN Farestone  
CN Toremifene  
CN Z-Toremifene  
FS STEREOSEARCH  
DR 98644-21-4  
MF C26 H28 Cl N O  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, CIN, DDFU,  
DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR,  
PROMT, RTECS\*, TOXLIT, ULIDAT, USAN, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

285 REFERENCES IN FILE CA (1967 TO DATE)  
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
285 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:302906  
REFERENCE 2: 135:288636  
REFERENCE 3: 135:266632  
REFERENCE 4: 135:251917  
REFERENCE 5: 135:251605  
REFERENCE 6: 135:220885  
REFERENCE 7: 135:205530  
REFERENCE 8: 135:205099  
REFERENCE 9: 135:204672  
REFERENCE 10: 135:190841

L16 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2001 ACS


RN 83647-34-1 REGISTRY

CN Phenol, 3-[(1E)-1-[4-[2-(ethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-(ethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-  
 FS STEREOSEARCH  
 MF C26 H29 N O2  
 LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261  
 REFERENCE 2: 132:102844  
 REFERENCE 3: 129:23441  
 REFERENCE 4: 105:42468  
 REFERENCE 5: 97:215730

L16 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN **83647-33-0** REGISTRY

CN Phenol, 3-[(1E)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-  
 OTHER NAMES:

CN K 106


CN N-Desmethyldroloxi-fene

FS STEREOSEARCH

MF C25 H27 N O2

LC STN Files: CA, CANCERLIT, CAPLUS, MEDLINE, TOXLIT, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

12 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
12 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261  
REFERENCE 2: 132:155208  
REFERENCE 3: 132:102844  
REFERENCE 4: 129:23441  
REFERENCE 5: 128:303587  
REFERENCE 6: 123:74089  
REFERENCE 7: 121:271199  
REFERENCE 8: 121:149116  
REFERENCE 9: 119:151738  
REFERENCE 10: 105:42468

L16 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 83647-31-8 REGISTRY

CN Phenol, 3-[(1E)-1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-  
OTHER NAMES:


CN K 089

FS STEREOSEARCH

MF C28 H33 N O2

LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261  
 REFERENCE 2: 132:102844  
 REFERENCE 3: 129:23441  
 REFERENCE 4: 123:330040  
 REFERENCE 5: 105:42468  
 REFERENCE 6: 102:89748  
 REFERENCE 7: 97:215730

L16 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 82413-20-5 REGISTRY

CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-,  
 (E)-

OTHER NAMES:

CN 3-Hydroxytamoxifen

CN Droloxifene

CN E-Droloxifene

CN K 060

CN K 060E

CN K 21.060E

FS STEREOSEARCH


MF C26 H29 N O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,

CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXLIT, ULIDAT, USAN, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

171 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 171 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:267223  
 REFERENCE 2: 135:205530  
 REFERENCE 3: 135:132470  
 REFERENCE 4: 135:117261  
 REFERENCE 5: 135:76700  
 REFERENCE 6: 135:71241  
 REFERENCE 7: 135:14359  
 REFERENCE 8: 134:348291  
 REFERENCE 9: 134:305328  
 REFERENCE 10: 134:305076

L16 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 68047-06-3 REGISTRY

CN Phenol, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-,  
 (Z)-


OTHER NAMES:

CN (Z)-4-Hydroxytamoxifen

CN 4-Hydroxytamoxifen

CN Hydroxytamoxifen  
 CN ICI 79280  
 CN trans-4-Hydroxytamoxifen  
 CN trans-Hydroxytamoxifen  
 FS STEREOSEARCH  
 DR 65213-48-1, 72732-26-4, 76276-99-8  
 MF C26 H29 N O2  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CAPLUS, CASREACT, CEN, CHEMCATS, CIN, CSCHEM, DDFU,  
 DRUGU, EMBASE, IPA, NIOSHTIC, PHAR, PROMT, RTECS\*, TOXLIT, USPATFULL  
 (\*File contains numerically searchable property data)

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

787 REFERENCES IN FILE CA (1967 TO DATE)  
 24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 790 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:313320  
 REFERENCE 2: 135:285335  
 REFERENCE 3: 135:268424  
 REFERENCE 4: 135:267692  
 REFERENCE 5: 135:267192  
 REFERENCE 6: 135:252144  
 REFERENCE 7: 135:252083  
 REFERENCE 8: 135:237592  
 REFERENCE 9: 135:236600  
 REFERENCE 10: 135:235901

L16 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2001 ACS  
 RN 64125-60-6 REGISTRY  
 CN Phenol, 3-methoxy-4-(3-methyl-2-butenyl)-5-[(1E)-2-phenylethenyl]- (9CI)  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Phenol, 3-methoxy-4-(3-methyl-2-butenyl)-5-(2-phenylethenyl)-, (E)-  
 OTHER NAMES:  
 CN Longistylin C  
 CN Longistylane C  
 FS STEREOSEARCH  
 MF C20 H22 O2  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, RTECS\*, TOXLIT  
 (\*File contains numerically searchable property data)

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1967 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:105025  
 REFERENCE 2: 104:126490  
 REFERENCE 3: 93:37284  
 REFERENCE 4: 92:110611  
 REFERENCE 5: 90:183143  
 REFERENCE 6: 87:117649

L16 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2001 ACS  
 RN 51023-76-8 REGISTRY  
 CN Benzenesulfonic acid, 5-(acetamido)-2-[2-(4-isothiocyanato-2-sulfophenyl)ethenyl]-, disodium salt (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Disodium 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonate  
 CN SITS  
 MF C17 H14 N2 O7 S3 . 2 Na  
 LC STN Files: ADISINSIGHT, AGRICOLA, BIOBUSINESS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MSDS-OHS, TOXLIT, USPATFULL  
 Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (27816-59-7)



●2 Na

146 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 146 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:314438  
 REFERENCE 2: 135:298460  
 REFERENCE 3: 135:31877  
 REFERENCE 4: 134:110420  
 REFERENCE 5: 133:218637  
 REFERENCE 6: 133:114784  
 REFERENCE 7: 133:13989  
 REFERENCE 8: 133:12415  
 REFERENCE 9: 132:305946  
 REFERENCE 10: 131:297859

L16 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 10540-29-1 REGISTRY

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)  
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-  
 CN Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-  
 (8CI)

OTHER NAMES:

CN ICI 47699  
 CN Mammaton  
 CN Tamofen  
 CN Tamoxifen  
 CN trans-Tamoxifen  
 CN Z-Tamoxifen  
 FS STEREOSEARCH  
 MF C26 H29 N O  
 CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,  
 CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES, DRUGNL,  
 DRUGPAT, DRUGU, EMBASE, HSDB\*, IPA, MEDLINE, MRCK\*, NIOSHTIC, PHAR,  
 PHARMASEARCH, PROMT, RTECS\*, SPECINFO, TOXCENTER, TOXLIT, ULIDAT, USAN,


USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4094 REFERENCES IN FILE CA (1967 TO DATE)

118 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

4108 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:316401  
 REFERENCE 2: 135:313756  
 REFERENCE 3: 135:313606  
 REFERENCE 4: 135:313519  
 REFERENCE 5: 135:313320  
 REFERENCE 6: 135:313271  
 REFERENCE 7: 135:313025  
 REFERENCE 8: 135:302906  
 REFERENCE 9: 135:300662  
 REFERENCE 10: 135:298909

L16 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 56-53-1 REGISTRY

CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, (E)- (8CI)

CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-

OTHER NAMES:

CN (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene

CN (E)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol

CN (E)-Diethylstilbestrol

CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol

CN .alpha.,.alpha.'-Diethylstilbenediol

CN 4,4'-Dihydroxy-.alpha.,.beta.-diethylstilbene

CN 4,4'-Dihydroxydiethylstilbene

CN Agostilben  
 CN Antigestil  
 CN Bio-des  
 CN Bufon  
 CN Comestrol  
 CN Cyren  
 CN Cyren A  
 CN Dawe's destrol  
 CN DEB  
 CN DES  
 CN DES (synthetic estrogen)  
 CN Di-Estryl  
 CN DiBestrol 2 Premix  
 CN Diethylstilbestrol  
 CN Distilbene  
 CN Domestrol  
 CN Estilbin MCO  
 CN Estrobene  
 CN Estromenin  
 CN Estrosyn  
 CN Fonatol  
 CN Grafestrol  
 CN Hi-Bestrol  
 CN Iscovesco  
 CN Menostilbeen  
 CN Microest  
 CN Milestrol  
 CN Neo-Oestranol I  
 CN Oestrogenine  
 CN Oestromenin  
 CN Oestromensyl  
 CN Pabestrol  
 CN Palestrol  
 CN Rumestrol 1  
 CN Rumestrol 2  
 CN Serral  
 CN Sexocretin  
 CN Sibol  
 CN Stil  
 CN Stil-Rol  
 CN Stilbestrol

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
 DISPLAY

FS STEREOSEARCH

DR 8026-45-7, 8028-09-9, 8030-34-0, 8049-42-1, 8053-00-7

MF C18 H20 O2

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,  
 CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DETHERM\*, DIOGENES, DRUGU,  
 EMBASE, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*,  
 MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS\*, SPECINFO, TOXLIT, ULIDAT, USAN,  
 USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4816 REFERENCES IN FILE CA (1967 TO DATE)  
 91 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 4821 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:314622  
 REFERENCE 2: 135:313797  
 REFERENCE 3: 135:313320  
 REFERENCE 4: 135:303215  
 REFERENCE 5: 135:299875  
 REFERENCE 6: 135:288636  
 REFERENCE 7: 135:288504  
 REFERENCE 8: 135:286909  
 REFERENCE 9: 135:284382  
 REFERENCE 10: 135:284251

L16 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2001 ACS

RN 50-41-9 REGISTRY

CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-,  
 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (1:1)  
 (8CI)

CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (6CI,  
 7CI)

OTHER NAMES:

CN 1-[p-(.beta.-Diethylaminoethoxy)phenyl]-1,2-diphenyl-2-chloroethylene  
 citrate

CN 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine dihydrogen citrate

CN Chloramiphen

CN Clomid

CN Clomifene citrate

CN Clomifeno

CN Clomiphene citrate

CN Clomiphene dihydrogen citrate


CN Clomivid

CN Clomphid

CN Clostilbegyt  
 CN Dyneric  
 CN Fertivet  
 CN Fertyl  
 CN Genozym  
 CN Ikaclomin  
 CN Mer 41  
 CN MRL 41  
 CN Omifin  
 CN Racemic clomiphene citrate  
 MF C26 H28 Cl N O . C6 H8 O7  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,  
 DIOGENES, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK\*, MSDS-OHS,  
 NIOSHTIC, PHARMASEARCH, PROMT, RTECS\*, TOXLIT, USAN, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)


CM 1

CRN 911-45-5  
 CMF C26 H28 Cl N O



CM 2

CRN 77-92-9  
 CMF C6 H8 O7



644 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 646 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:268418  
 REFERENCE 2: 135:267389  
 REFERENCE 3: 135:221503

REFERENCE 4: 135:221432  
REFERENCE 5: 135:221411  
REFERENCE 6: 135:205651  
REFERENCE 7: 135:116199  
REFERENCE 8: 135:71383  
REFERENCE 9: 134:290552  
REFERENCE 10: 134:285588

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 09:57:22 ON 19 NOV 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 Nov 2001 VOL 135 ISS 22  
 FILE LAST UPDATED: 18 Nov 2001 (20011118/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.


HCAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=>

=>

=> d stat que 119

L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L7 65281 SEA FILE=REGISTRY SSS FUL L1

L11 40827 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

L12 99 SEA FILE=HCAPLUS ABB=ON PLU=ON L11(L) (BONE(2A) (LOSS OR RESORP?) OR ?OSTEOP? OR ?HYPERTENS? OR (BLD OR BLOOD) (W)PRESSURE)

L14 978 SEA FILE=HCAPLUS ABB=ON PLU=ON L7(L) (?MEDIC? OR ?PHARM? OR

?DRUG? OR ?THERP?)  
 L15 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND L12  
 L18 61 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 NOT (2001 OR 2000 OR  
 1999)/PY  
 L19 56 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 NOT L15

=&gt;

=&gt;

=&gt; d ibib abs hitrn 119 1-25;d ibib hitrn 119 26-56

L19 ANSWER 1 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:763283 HCAPLUS

DOCUMENT NUMBER: 130:119562

TITLE: Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats

AUTHOR(S): Nuttall, Mark E.; Bradbeer, Jeremy N.; Stroup, George B.; Nadeau, Daniel P.; Hoffman, Sandra J.; Zhao, Hugh; Rehm, Sabine; Gowen, Maxine

CORPORATE SOURCE: Departments of Bone and Cartilage Biology, and Safety Assessment (SR), SmithKline Beecham Pharmaceuticals, King of Prussia, PA, 19406, USA

SOURCE: Endocrinology (1998), 139(12), 5224-5234

CODEN: ENDOAO; ISSN: 0013-7227

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Idoxifene, a novel selective estrogen receptor modulator, was tested for its effects on bone loss, serum cholesterol, and uterine wet wt. and histol. in the ovariectomized (Ovx) rat. Idoxifene (0.5 mg/kg.cntdot.day) completely prevented loss of both lumbar and proximal tibial bone mineral d. (BMD). In an intervention study, idoxifene (0.5 and 2.5 mg/kg.cntdot.day) completely prevented further loss of both lumbar and proximal tibial BMD during a 2-mo treatment period commencing 1 mo after surgery, when significant loss of BMD had occurred in the Ovx control group. Idoxifene reduced total serum cholesterol, which was maximal at 0.5 mg/kg.cntdot.day. Idoxifene alone displayed minimal uterotrophic activity in Ovx rats and inhibited the agonist activity of estrogen in intact rats. Histol., myometrial and endometrial atrophy were obsd. in both idoxifene and vehicle-treated Ovx rats. The authors also provide mol.-based evidence to support the observations in vivo of a novel selective estrogen receptor modulator (SERM) mechanism of action in bone and endometrial cells. Idoxifene is an agonist through the estrogen response element (ERE) and exhibits similar postreceptor effects to estrogen in bone-forming osteoblasts. Idoxifene also stimulates osteoclast apoptosis, and these pleiotropic effects ultimately could contribute to the maintenance of bone homeostasis. However, idoxifene differs from estrogen in a tissue-specific manner. In human endometrial cells, where estrogen is a potent agonist through the ERE, idoxifene has negligible agonist activity. Moreover, idoxifene was able to block estrogen induced gene expression in endometrial cells, which is in agreement with the observation in the intact rat study. In the uterus, idoxifene has a pharmacol. favorable profile, lacking agonist and therefore growth-promoting activity. Together with its cholesterol lowering effect and lack of uterotrophic activity, these data suggest that idoxifene may be effective in the prevention of osteoporosis and other

postmenopausal diseases without producing unwanted estrogenic effects on the endometrium.

IT **116057-75-1**, Idoxifene

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Idoxifene prevents **bone loss** and lowers cholesterol levels in ovariectomized rats and decreases uterine wt. in intact rats)

REFERENCE COUNT: 46

REFERENCE(S): (3) Beresford, J; Endocrinology 1986, V119, P1776 HCAPLUS

(6) Chander, S; Cancer Res 1991, V51, P5851 HCAPLUS

(7) Clover, J; Bone 1994, V15, P585 HCAPLUS

(9) Frenkel, B; Biochemistry 1993, V32, P13636 HCAPLUS

(10) Furr, B; The Pharmacology and clinical uses of tamoxifen Pharmacol Therap 1984, V25, P127 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:430074 HCAPLUS

DOCUMENT NUMBER: 129:100036

TITLE: Combination therapy to treat osteoporosis - polyphosphonates and estrogen agonists

INVENTOR(S): MacLean, David B.; Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5773477	A	19980630	US 1997-803707	19970221

OTHER SOURCE(S): MARPAT 129:100036

GI



AB A novel method of treating or preventing osteoporosis in mammals comprises administering an effective amt. of an estrogen agonist (I; R1, R2 =, Me, Et, PhCH2; when R1 = R2, each is Me or Et; when R1  $\neq$  R2, one is Me or Et and the other is H or PhCH2) or pharmaceutically acceptable salt thereof, together with a bone resorption-inhibiting polyphosphonate. Thus, tablets were prepd. contg. active ingredients 0.25-100, starch 45, microcryst. cellulose 35, PVP (as 10% aq. soln.) 4, Na CM-cellulose 4.5, Mg stearate 0.5, and talc 1 wt. parts.

IT **165813-04-7**

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)  
 (5combination therapy to treat **osteoporosis**: polyphosphonates  
 and estrogen agonists)

IT 165813-01-4 165813-02-5 165813-03-6  
 209684-21-9 209684-24-2 209684-27-5  
 209684-29-7 209684-31-1 209684-33-3  
 209684-35-5 209684-38-8

RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination therapy to treat **osteoporosis**: polyphosphonates  
 and estrogen agonists)

L19 ANSWER 3 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:402319 HCAPLUS

DOCUMENT NUMBER: 129:86015

TITLE: Methods and compositions for preventing and treating  
 bone loss

INVENTOR(S): Fuh, Vivian L.; Kaufman, Keith D.; Waldstreicher,  
 Joanne

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Fuh, Vivian L.; Kaufman, Keith  
 D.; Waldstreicher, Joanne

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825623	A1	19980618	WO 1997-US22344	19971205
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9855943	A1	19980703	AU 1998-55943	19971205
PRIORITY APPLN. INFO.:			US 1996-32635	19961209
			GB 1997-221	19970108
			US 1997-47174	19970520
			WO 1997-US22344	19971205

AB The present invention provides for a method of inhibiting bone loss in a subject in need of such treatment comprising administration of a therapeutically effective amt. of the 5.alpha.-reductase type 2 inhibitor finasteride to the subject. The present invention further provides for a method for treating and preventing osteoporosis and osteopenia and other diseases where inhibiting bone loss may be beneficial, including: Paget's disease, malignant hypercalcemia, periodontal disease, joint loosening and metastatic bone disease, comprising administration of therapeutically effective amt. of the 5.alpha.-reductase type 2 inhibitor finasteride to the subject. Further, the present invention provides for compns. useful in the methods of the present invention, as well as a method of manuf. of a medicament useful for inhibiting bone loss and treating or preventing osteoporosis and osteopenia. The effect of finasteride on bone mineral d. in men was studied and formulations contg. finasteride were given. Bone anabolic agents, bone antiresorptive agents, estrogens, or antiestrogens may be added to the compns.

IT 911-45-5, Clomiphene 5863-35-4, CI-628  
 15690-55-8, Zuclophene 15690-57-0, Enclomiphene  
 56287-31-1, CI-680  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (5.alpha.-reductase type 2 inhibitor compns. for preventing and  
 treating bone loss)

L19 ANSWER 4 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1998:402318 HCAPLUS  
 DOCUMENT NUMBER: 129:67926  
 TITLE: Methods and compositions for preventing and treating  
 bone loss  
 INVENTOR(S): Fuh, Vivian L.; Kaufman, Keith D.; Waldstreicher,  
 Joanne  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Fuh, Vivian L.; Kaufman, Keith  
 D.; Waldstreicher, Joanne  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825622	A1	19980618	WO 1997-US22050	19971205
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9857916	A1	19980703	AU 1998-57916	19971205
PRIORITY APPLN. INFO.:			US 1996-32636	19961209
			GB 1997-220	19970108
			WO 1997-US22050	19971205
OTHER SOURCE(S):		MARPAT 129:67926		
GI				



AB Azasteroids of formula I [R1 = H, alkyl; R2, R3 = alkyl] are prepd. for  
 use in inhibiting bone loss. The present invention further provides for a

method for treating and preventing osteoporosis and osteopenia and other diseases where inhibiting bone loss may be beneficial, including: Paget's disease, malignant hypercalcemia, periodontal disease, joint loosening and metastatic bone disease, comprising administration of therapeutically effective amt. of I to the subject. Thus, II is prepd. from pregnenolone acetate in several steps. Pharmaceutical compns. contg. I are described.

IT 911-45-5, Clomiphene 5863-35-4, CI-628  
15690-55-8, Zuclomiphene 15690-57-0, Enclomiphene  
56287-31-1, CI-680  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of azasteroids for preventing and treating **bone loss**)

L19 ANSWER 5 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1997:273968 HCAPLUS  
DOCUMENT NUMBER: 126:338657  
TITLE: Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats  
AUTHOR(S): Jimenez, M. A.; Magee, D. E.; Bryant, H. U.; Turner, R. T.  
CORPORATE SOURCE: Department Orthopedics Biochemistry Molecular Biology, Mayo Clinic, Rochester, MN, 55905, USA  
SOURCE: Endocrinology (1997), 138(5), 1794-1800  
CODEN: ENDOAO; ISSN: 0013-7227  
PUBLISHER: Endocrine Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Estrogen inhibits postmenopausal bone loss and decreases fracture risk. Unfortunately, estrogen replacement therapy has many undesirable side effects, the majority of which are due to stimulation of reproductive tissues. Tissue specific estrogen agonists provide a promising new alternative to natural estrogens for hormone replacement. Clomiphene (CLO) is a substituted triphenylethylene antiestrogen based on its ability to antagonize estrogen-mediated uterine growth in rodents. CLO is used clin. for the treatment of disorders of ovulation in patients wishing to become pregnant. To det. whether CLO has tissue selective actions, we performed a dose-response study in adult (6-mo-old) ovariectomized (OVX'd) rats. The rats received daily (gavage) doses of either 17  $\alpha$ -ethynylestradiol (E) (0.1 mg/kg) or CLO (0.01-10 mg/kg) daily for 5 wk. Long-term loss of ovarian function had no effect on serum cholesterol, greatly decreased uterine wt., cancellous bone area and trabecular no., and increased bone formation rate (BFR) and osteoblast and osteoclast perimeters. E treatment of OVD'd rats prevented uterine atrophy, greatly lowered cholesterol, and prevented many of the bone changes. CLO was a very weak estrogen agonist in supporting uterine wt., a partial agonist in reducing serum cholesterol, and an excellent agonist in maintaining normal bone mass and indexes of bone turnover. We conclude from these studies that CLO exhibits pronounced tissue selective estrogen agonism in the rat. Specifically, CLO is effective in preventing cancellous bone loss in the OVD'd rats and has minimal uterotrophic activity.

IT 911-45-5, Clomiphene  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(clomiphene prevents cancellous **bone loss** from  
tibia of ovariectomized rats)

L19 ANSWER 6 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:214315 HCAPLUS  
 DOCUMENT NUMBER: 126:272315  
 TITLE: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study  
 AUTHOR(S): Delmas, P.D.; Balena, R.; Confravreux, E.; Hardouin, C.; Hardy, P.; Bremond, A.  
 CORPORATE SOURCE: INSERM Research Unit 403, Hopital E. Herriot, Lyon, 69437, Fr.  
 SOURCE: J. Clin. Oncol. (1997), 15(3), 955-962  
 CODEN: JCONDN; ISSN: 0732-183X  
 PUBLISHER: Saunders  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The purpose of this study is to det. the effectiveness and safety of the bisphosphonate risedronate in preventing bone loss in young women with breast cancer and early menopause induced by chemotherapy who are at major risk for the development of postmenopausal osteoporosis. Fifty-three white women, aged 36 to 55 yr, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use. Thirty-six patients received tamoxifen (20 mg/d). Within each stratum, patients were randomly assigned to receive risedronate (n = 27) or placebo (n = 26). Treatment consisted of eight cycles oral risedronate 30 mg/d or placebo daily for 2 wk followed by 10 wk of no drug (12 wk per cycle). Patients were monitored for a third year without treatment. Main outcomes of the study were changes in lumbar spine and proximal femur (femoral neck, trochanter, and Ward's triangle) bone mineral d. (BMD), and biochem. markers of bone turnover. In contrast to a significant decrease of BMD at the lumbar spine and hip in the placebo group, there was an increase in BMD in the risedronate group. On treatment withdrawal, bone loss ensued, which suggests that treatment needs to be continuous to maintain a protective effect on bone mass. At 2 yr, the mean difference (± SEM) between groups was 2.5% ± 1.2%, (95% confidence interval [CI], 0.2 to 4.9) at the lumbar spine (P = .041) and 2.6% ± 1.1%, (95% CI, 0.3 to 4.8) at the femoral neck (P = .029). Similar results were obsd. at the hip trochanter. Results by stratum indicate a beneficial, although partial, effect of tamoxifen in reducing bone loss. Risedronate was well tolerated and showed a good safety profile, with no evidence of lab. abnormalities. Risedronate appears to be a safe treatment that prevents both trabecular and cortical bone loss in women with menopause induced by chemotherapy for breast cancer.

IT 10540-29-1, Tamoxifen

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bisphosphonate risedronate prevents **bone loss** in women with artificial menopause due to chemotherapy of breast cancer)

L19 ANSWER 7 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:312445 HCAPLUS  
 DOCUMENT NUMBER: 125:25752  
 TITLE: Regulation of avian osteoclastic H<sup>+</sup>-ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors  
 AUTHOR(S): Williams, John P.; Blair, Harry C.; McKenna, Margaret A.; Jordan, S. Elizabeth; McDonald, Jay M.  
 CORPORATE SOURCE: Dep. Pathol., Univ. Alabama, Birmingham, AL, 35294, USA

SOURCE: J. Biol. Chem. (1996), 271(21), 12488-12495  
 CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We used highly purified chicken osteoclasts and isolated membranes from osteoclasts to study effects of tamoxifen, 4-hydroxytamoxifen, calmodulin antagonists, estrogen, diethylstilbestrol, and the anti-estrogen ICI 182780 on cellular degrdn. of 3H-labeled bone in vitro and on membrane HCl transport. Bone resorption was reversibly inhibited by tamoxifen, 4-hydroxytamoxifen, and trifluoperazine with IC50 values of .apprx.1 .mu.M. Diethylstilbestrol and 17-.beta.-estradiol had no effects on bone resorption at receptor-satg. concns., while ICI 182780 inhibited bone resorption at concns. greater than 1 .mu.M. At these concns. ICI 182780, like tamoxifen, inhibits calmodulin-stimulated cyclic nucleotide phosphodiesterase activity. Membrane HCl transport, assessed by ATP-dependent acridine orange uptake, was unaffected by 17-.beta.-estradiol and diethylstilbestrol at concns. up to 10 .mu.M, whole ICI 182780 inhibited HCl transport at concns. greater than 1 .mu.M. In contrast HCl transport was inhibited by tamoxifen, 4-hydroxytamoxifen, and the calmodulin antagonists, trifluoperazine and calmidazolium, with IC50 values of 0.25-1.5 .mu.M. These results suggested the presence of a membrane-assocd. non-steroid receptor for tamoxifen in osteoclasts. Tamoxifen binding studies demonstrated saturable binding in the osteoclast particulate fraction, but not in the nuclear or cytosolic fractions. Membranes enriched in ruffled border by differential centrifugation following nitrogen cavitation showed binding consistent with one site, Kd .apprx.1 .mu.M. Our findings indicate that tamoxifen inhibits osteoclastic HCl transport by binding membrane-assocd. target(s), probably similar or related to calmodulin antagonist targets. Further, effects of estrogens or highly specific anti-estrogens on bone turnover do not support the hypothesis of a direct effect on osteoclasts by these compds. in this species.

IT 10540-29-1, Tamoxifen  
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
 (regulation of avian osteoclastic H+-ATPase and **bone resorption** by tamoxifen and calmodulin antagonists is independent of steroid receptors)

L19 ANSWER 8 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:82434 HCAPLUS

DOCUMENT NUMBER: 124:134461

TITLE: Organ-selective actions of tamoxifen and other partial antiestrogens

AUTHOR(S): Turner, R. T.

CORPORATE SOURCE: Dep. Orthop. Res., Mayo Clin. Found., Rochester, NY, 55905, USA

SOURCE: Ernst Schering Res. Found. Workshop (1995), Volume Date 1995, 16, 65-84

CODEN: ESRWEL; ISSN: 0947-6075

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with many refs. of prevention of and therapy for postmenopausal osteoporosis with estrogen agonists and antagonists.

IT 10540-29-1, Tamoxifen  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (organ-selective actions of tamoxifen and other partial antiestrogens and therapy for postmenopausal **osteoporosis**)

L19 ANSWER 9 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1996:26510 HCAPLUS  
 DOCUMENT NUMBER: 124:105293  
 TITLE: Anti-estrogens and postmenopausal osteoporosis  
 AUTHOR(S): Draper, Michael W.  
 CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company,  
 Indianapolis, IN, USA  
 SOURCE: J. Bone Miner. Metab. (1994), Volume Date 1994,  
 12(Suppl. 2), S21-S23  
 CODEN: JBMME4; ISSN: 0914-8779  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review with 8 refs. Many agents in the estrogen-antiestrogen class may  
 have potential as effective antiresorptives in the treatment of  
 osteoporosis. Several studies have now established the therapeutic  
 potential of tamoxifen in this field. Raloxifene is a new agent, which  
 may show promise in the therapy of osteoporosis.  
 IT 10540-29-1, Tamoxifen  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (anti-estrogens and postmenopausal **osteoporosis**)

L19 ANSWER 10 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1996:17239 HCAPLUS  
 DOCUMENT NUMBER: 124:106966  
 TITLE: Effects of droloxifene on prevention of cancellous  
 bone loss and bone turnover in the axial skeleton of  
 aged, ovariectomized rats  
 AUTHOR(S): Ke, H. Z.; Chen, H. K.; Qi, H.; Pirie, C. M.; Simmons,  
 H. A.; Ma, Y. F.; Jee, W. S. S.; Thompson, D. D.  
 CORPORATE SOURCE: Department Metabolic Diseases, Pfizer Inc., Groton,  
 CT, 06340, USA  
 SOURCE: Bone (1995), 17(5), 491-6  
 CODEN: BONEDL; ISSN: 8756-3282  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The purpose of this study was to det. the efficacy of droloxifene (DRO),  
 an estrogen antagonist/agonist, in preventing ovariectomy (OVX)-induced  
 lumbar vertebral cancellous bone loss and bone turnover in aged female  
 rats. Fifty-three Sprague-Dawley female rats were OVX or sham-operated at  
 19 mo of age, and divided into 6 groups: (I) sham-operated controls; (II)  
 OVX vehicle controls; (III) OVX rats treated with E2 at 30 .mu.g/kg/day;  
 (IV)-(VI) OVX rats treated with DRO at either 2.5, 5, or 10 mg/kg p.o.  
 daily. The treatment period was 8 wk. Static and dynamic cancellous bone  
 histomorphometric parameters were detd. on 4 and 10 .mu.m thick,  
 undecalcified, double-fluorescent labeled sections of the fourth lumbar  
 vertebral body. Changes in body wt., uterine wt., and total serum  
 cholesterol were also detd. OVX for 8 wk in 19-mo-old female rats  
 resulted in reduced trabecular bone vol. (-18%) and trabecular width  
 (-10%) and increased labeling perimeter (+52%), bone formation rate/bone  
 surface referent (+60%), bone formation rate/bone vol. referent (+77%),  
 osteoclast no. (+41%), and osteoclast perimeter (+41%). E2 treatment at  
 30 .mu.g/kg/day for 8 wk prevented OVX-induced cancellous bone loss and  
 decreased bone resorption, bone formation, and bone turnover to the values  
 of sham controls. DRO at 2.5-10 mg/kg/day completely prevented bone loss  
 and bone turnover assocd. with estrogen deficiency. Osteoclast no. and  
 perimeter were significantly decreased in DRO-treated-OVX rats compared to  
 both sham and OVX controls. Trabecular bone vol., trabecular width,  
 labeling perimeter, bone formation rate/bone surface referent, and bone

formation rate/bone vol. referent showed no differences in DRO-treated OVX rats compared to those of E2-treated OVX rats and sham controls. These histomorphometric results indicated that DRO is an estrogen agonist on cancellous bone of lumbar vertebral bodies of aged, OVX rats. Further, E2 treatment prevented the OVX-induced increase in body wt. gain and nonsignificantly reduced total serum cholesterol compared to OVX controls. Body wt. gain and total serum cholesterol did not differ between OVX rats treated with E2 and sham controls. In OVX rats treated with DRO, body wt. decreased significantly in a dose-response manner, and total serum cholesterol was significantly reduced by 65% to 70% compared to both sham and OVX controls. In addn., treatment with E2 increased uterine wt. to the value of sham controls in OVX rats. However, DRO had no effect on uterine wt. at either 2.5 or 10 mg/kg/day, while it only slightly but significantly increased uterine wt. over OVX controls at 5 mg/kg/day. The authors conclude that DRO was efficacious in the prevention of lumbar vertebral cancellous bone loss and in the decline of total serum cholesterol but had no effect on uterine wt. in the aged, OVX female rats. The data suggest that DRO is a potentially useful agent for the prevention of vertebral bone loss leading to spinal fractures in postmenopausal women.

IT 82413-20-5, Droloxifene

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effects of droloxifene on prevention of cancellous bone loss and bone turnover in axial skeleton of aged, ovariectomized rats)

L19 ANSWER 11 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:730370 HCAPLUS

DOCUMENT NUMBER: 123:160785

TITLE: Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy x-ray absorptiometric and histomorphometric study  
AUTHOR(S): Chen, Hong Ka; Ke, Hua Zhu; Jee, Webster S. S.; Ma, Yan Fei; Pirie, Christine M.; Simmons, Hollis A.; Thompson, David D.

CORPORATE SOURCE: Division of Radiobiology, Univ. of Utah Sch. of Medicine, Salt Lake City, UT, USA

SOURCE: J. Bone Miner. Res. (1995), 10(8), 1256-62

DOCUMENT TYPE: CODEN: JBMREJ; ISSN: 0884-0431

LANGUAGE: Journal English

AB Our previous studies indicated that droloxifene (DRO), a tissue-specific estrogen antagonist/agonist, prevented bone loss without causing uterine hypertrophy in growing ovariectomized (OVX) rats. Using dual-energy x-ray absorptiometry (DXA) and bone histomorphometry, the current study compared the efficacy of DRO to 17 $\beta$ -estradiol (E2) in preventing OVX-induced bone loss in tibiae and femora of 19-mo-old rats to det. whether DRO had similar skeletal effects as E2 in aged female rats. Sprague-Dawley female rats were OVX or sham-operated (sham) at 19 mo of age. The sham-operated rats were treated with vehicle (oral), while the OVX rats were treated with vehicle (oral), E2 at 30  $\mu$ g/kg/day (s.c.), or DRO at 2.5, 5, or 10 mg/kg/day (oral) for 8 wk. Bone mineral d. (BMD) of whole femora (WF), distal femoral metaphyses (DFM), femoral shafts (FS), and proximal femora (PF) was detd. using DXA. Static and dynamic cancellous bone histomorphometric analyses were performed in double-labeled undecalcified longitudinal sections from proximal tibial metaphyses. Ovariectomy for 8 wk significantly reduced the BMD of WF, DFM, FS, and PF (from -6 to -15%). Treatment with E2 completely prevented the decreases in BMD of WF and DFM

and had no significant effects in BMD of FS and PF in aged OVX rats. The decrease in BMD of DFM induced by OVX was prevented by treatment with DRO at all dose levels. In addn., DRO at 10 mg/kg/day prevented OVX-induced decreases in BMD of WF, FS, and PF. Furthermore, proximal tibial cancellous bone histomorphometric results showed that OVX significantly decreased the trabecular bone vol. by 34% and increased the activation frequency by 104% while it nonsignificantly increased other indexes including percent eroded perimeter, mineral apposition rate, and bone formation rate per bone vol. compared with sham-operated controls. Treatment with E2 or DRO at all dose levels completely prevented the OVX-induced decreases in trabecular bone vol. and increases in bone turnover, indicating that DRO is an estrogen agonist in bone in aged OVX rats. Together with the previous findings that DRO inhibited body wt. gain, reduced total serum cholesterol, and had no effect on uterine wt., we conclude that DRO is as efficacious as E2 in preventing OVX-induced bone loss and inhibiting bone turnover but without estrogenic uterine effects in aged OVX rats. These data suggest that DRO may be superior to E2 for the treatment of postmenopausal and senile osteoporosis.

IT 82413-20-5, Droloxifene

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(droloxifene prevention of ovariectomy-induced bone loss in relation to osteoporosis treatment)

L19 ANSWER 12 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:575349 HCAPLUS

DOCUMENT NUMBER: 122:306275

TITLE: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats

AUTHOR(S): Ke, Hua Zhu; Simmons, Hollis A.; Pirie, Christine M.; Crawford, D. Todd; Thompson, David D.

CORPORATE SOURCE: Dep. Cardiovascular Metabolic Siseases, Central Res. Div., Groton, CT, 06340, USA

SOURCE: Endocrinology (1995), 136(6), 2435-41  
CODEN: ENDOAO; ISSN: 0013-7227

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to det. the effects of droloxifene (DRO), a new estrogen antagonist/agonist, on bone turnover, bone mass, total serum cholesterol, and uterine wt. in rats made estrogen deficient by ovariectomy. Sprague-Dawley female rats were ovariectomized (OVX) or sham operated (sham) at 5 mo of age and treated with 17.beta.-estradiol (E2) at 30 .mu.g/kg, s.c., daily or with DRO at 5, 10, or 20 mg/kg.cntdot.day, orally, for 4 wk. At the time of death, body wt. gain, uterine wt., and total serum cholesterol were measured. Bone area, bone mineral content (BMC), and bone mineral d. (BMD) of whole femora, distal femoral metaphases, femoral shaft, and proximal femora were detd. ex vivo using dual energy x-ray absorptiometry. Static and dynamic cancellous bone histomorphometric anal. of proximal tibial metaphyses was performed in double fluorescent labeled, undecalcified, 4- and 10-.mu.m longitudinal sections. Body wt. gain in E2-treated OVX rats was significantly reduced compared to that in OVX controls, but was not different from that in sham controls. Body wt. gain in DRO-treated OVX rats was decreased significantly compared to that in both sham and OVX controls. In OVX rats, uterine wt. was completely preserved by treatment with E2. Uterine wt. in DRO-treated OVX rats was slightly, but significantly, increased from the vehicle-treated control value, and was significantly lower than that in sham controls and E2-treated OVX rats. Treatment with s.c. injection of E2 in OVX rats had no effect on total serum cholesterol,

whereas OVX rats orally treated with DRO at 5-20 mg/kg.cntdot.day decreased total serum cholesterol by 33-46% compared to levels in sham and OVX controls. Compared to sham controls, OVX decreased BMC and BMD of distal femoral metaphyses, increased BMD of the femoral shaft, and had no effect on BMC and BMD of whole femora and proximal femora. Treatment with either E2 or DRO prevented these changes induced by OVX. Proximal tibial metaphyseal trabecular bone vol. and trabecular no. were increased, and trabecular sepn., percent osteoclast perimeter, osteoclast no., percent mineralizing perimeter, mineral apposition rate, bone formation rate, and bone turnover rate were decreased in 5, 10, or 20 mg/kg.cntdot.day DRO-treated OVX rats compared to OVX controls. These cancellous bone histomorphometric indexes in DRO-treated OVX rats did not differ from those in E2-treated OVX rats or sham controls, suggesting that DRO completely prevented the increases in bone turnover and the decrease in bone mass induced by OVX in rats. The results demonstrate that DRO prevented increased bone turnover and bone loss, reduced total serum cholesterol, and caused minimal uterine hypertrophy in 5-mo-old OVX rats. These data suggest that DRO is an estrogen agonist on bone and may be an effective alternative to estrogen for the prevention of postmenopausal osteoporosis.

IT 82413-20-5, Droloxifene

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats)

L19 ANSWER 13 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:417462 HCAPLUS

DOCUMENT NUMBER: 122:170182

TITLE: Therapeutics for treatment of osteoporosis

INVENTOR(S): Miki, Shuji; Kanehira, Koichi; Matsumoto, Toshio

PATENT ASSIGNEE(S): Kuraray Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06312930	A2	19941108	JP 1993-128036	19930430
AB	The title therapeutic compns. (e.g. tablets) contain progestogens and estrogen antagonists as active ingredients. Administration of progesterone (I) and 16.beta.-ethylestradiol (II) at 25 mg/kg and 50 .mu.g/kg, resp., s.c. for 2 wk to bone morphogenetic protein-treated rats resulted in bone mineral increase by 60%, vs. -6% or 14%, resp. for I or II alone.			
IT	10540-29-1, Tamoxifen			
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mixt. contg., combination use of progestogens and estrogen antagonists for treatment of <b>osteoporosis</b> )				

L19 ANSWER 14 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:333200 HCAPLUS

DOCUMENT NUMBER: 122:96017

TITLE: Antiestrogens inhibit in vitro bone resorption stimulated by 1,25-dihydroxyvitamin D3 and the vitamin

D3 analogs EB1089 and KH1060  
 AUTHOR(S): Vink-van Wijngaarden, Trudy; Birkenhaeager, Jan C.;  
 Kleinekoort, Wendy M. C.; van den Bernd, Gert-Jan C.  
 CORPORATE SOURCE: M.; Pols, Huibert A. P.; van Leeuwen, P. T. M.  
 Dep. Internal Med. III, Erasmus Univ. Med. Sch.,  
 SOURCE: Rotterdam, 3000 DR, Neth.  
 Endocrinology (1995), 136(2), 812-15  
 CODEN: ENDOAO; ISSN: 0013-7227  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) has been shown to inhibit breast cancer cell growth both in vitro and in vivo. A major drawback is that high doses of 1,25-(OH)2D3 are needed which may result in undesirable side effects like the development of hypercalcemia and an increased risk of bone metastases due to the stimulation of bone resorption by 1,25-(OH)2D3. Several newly developed 1,25-(OH)2D3 analogs have a reduced calcemic activity, but their effects on bone resorption have not yet been examd. Presently, the antiestrogen tamoxifen is the most important endocrine therapy for breast cancer. Recent studies have demonstrated the benefit of the combination tamoxifen and 1,25-(OH)2D3/analog for the inhibition of breast cancer cell growth. Besides inhibition of breast cancer growth tamoxifen appeared to have beneficial effects on bone. The purpose of the present study was to investigate the effect of tamoxifen on 1,25-(OH)2D3- and analogs (EB 1089 and KH 1060)-stimulated bone resorption in an in vitro model. Bone resorption was stimulated by 1,25-(OH)2D3 and analogs in a dose-dependent manner with KH 1060 and EB 1089 being more potent than 1,25-(OH)2D3. Tamoxifen caused a strong dose-dependent inhibition (70% at 10 .mu.M) of 1,25-(OH)2D3- and EB 1089-stimulated bone resorption. KH 1060-stimulated bone resorption was also inhibited by tamoxifen but to a lesser extent (36%). Also the pure antiestrogen ICI164,384 but not 17.beta.-estradiol inhibited 1,25-(OH)2D3-stimulated bone resorption. Together, this study demonstrates that tamoxifen considerably reduces 1,25-(OH)2D3/analog-stimulated bone resorption and therefore may be useful to reduce the risk of bone metastases. This together with the obsd. beneficial effects on breast cancer cell growth indicates that tamoxifen together with 1,25-(OH)2D3/analog is an interesting combination for the treatment of breast cancer. The mechanism of the bone resorption inhibitory action is not yet known but seems to be independent of the estrogen pathway.

IT 10540-29-1, Tamoxifen  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antiestrogens inhibit in vitro **bone resorption**  
 stimulated by 1,25-dihydroxyvitamin D3 and vitamin D3 analogs EB1089 and KH1060)

L19 ANSWER 15 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1994:646209 HCAPLUS  
 DOCUMENT NUMBER: 121:246209  
 TITLE: In the ovariectomized rat, tamoxifen conserves bone similarly in parathyroid-intact and parathyroidectomized animals  
 AUTHOR(S): Goulding, A.; Gold, E.  
 CORPORATE SOURCE: Department Medicine, University Otago, Dunedin, N. Z.  
 SOURCE: Bone (1994), 15(5), 497-503  
 CODEN: BONEDL; ISSN: 8756-3282  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB To examine the ability of tamoxifen (TAM) to conserve bone in the

estrogen-deficient ovariectomized (OVX) rat in the presence and absence of parathyroid hormone (PTH) six groups of rats with  $^{45}\text{Ca}$ -labeled bones were studied for 12 wk. Rats were OVX, parathyroidectomized (PTX), or given sham operations and treated with TAM (10 mg/kg body wt./wk s.c.) or TAM-vehicle. Treatments were: group 1 = Sham-OVX; group 2 = Sham-OVX + TAM; group 3 = OVX; group 4 = OVX + TAM; group 5 = OVX + PTX; and group 6 = OVX + PTX + TAM. To monitor bone resorption serial measurements of urinary hydroxyproline and  $^{45}\text{Ca}$  excretion were made during the study. Ovariectomy raised these markers of bone breakdown and caused significant osteopenia, whereas TAM prevented ovariectomy increasing urinary hydroxyproline or  $^{45}\text{Ca}$  and conserved bone. Final total body calcium values (TBCa) in groups 1-6, resp., were (mg  $\pm$  SD): 3240  $\pm$  300; 3260  $\pm$  289; 2750  $\pm$  231; 3212  $\pm$  312; 2742  $\pm$  199; and 3387  $\pm$  252. Thus ovariectomy reduced TBCa similarly in the presence and absence of the parathyroids ( $p < 0.001$ ). In contrast TAM fully protected both PT-intact and PTX rats from the osteopenic effect of ovariectomy, despite the fact that PTX rats had a lower rate of bone turnover than PT-intact rats. However, TAM-treated OVX rats had shorter femora than OVX rats given TAM-vehicle, suggesting that TAM suppresses growth of the long bones to some degree in estrogen-deficient animals. We conclude that, in the rat, TAM conserves the skeleton from estrogen-deficiency bone loss independently of changes in PT function. Estrogen-deficiency bone loss is no greater in rats with a high rate of PTH-mediated bone breakdown than in rats with a low rate of PTH-mediated bone turnover.

IT 10540-29-1, Tamoxifen

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tamoxifen conserves skeleton from estrogen-deficiency bone loss independently of changes in parathyroid function)

L19 ANSWER 16 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:290331 HCAPLUS

DOCUMENT NUMBER: 120:290331

TITLE: Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption  
AUTHOR(S): Turner, Russell T.; Evans, Glenda L.; Wakley, Glenn K.  
CORPORATE SOURCE: Dep. Orthop. Surg., Mayo Found., Rochester, MN, USA  
SOURCE: J. Bone Miner. Res. (1993), 8(3), 359-66  
CODEN: JBMREJ; ISSN: 0884-0431  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Ovariectomy results in cancellous osteopenia in rat long bones, a condition that is prevented by treatment with estrogens. The purpose of these studies was to clarify the effects of estrogen on cancellous bone turnover using dynamic bone histomorphometry. Treatment of ovariectomized rats with DES reduced the mineral apposition rate, double-label perimeter, osteoblast no., suggesting that the hormone had inhibitory effects on bone formation as well as bone resorption. However, the authors could not est. the bone formation rate because of rapid resorption of tetracycline-labeled bone in the ovariectomized rat. The magnitude of loss was documented by a time course study: 58% of the tetracycline initially incorporated into the secondary spongiosa of the tibial metaphysis was resorbed after 11 days and 89% was resorbed after 22 days. Similarly, cancellous bone area was decreased by 67% after 11 days and by 88% after 22 days. Administration of either DES or tamoxifen (TAM) dramatically reduced resorption of tetracycline as well as the decrease in cancellous bone area. These results demonstrate that (1) estrogen prevents osteopenia in ovariectomized (OVX) rats, in part by inhibiting

bone turnover, (2) TAM is an estrogen agonist on bone resorption, and (3) resorption of tetracycline-labeled bone leads to serious underestimation of the bone formation rate in OVX rats.

IT 56-53-1, Diethylstilbesterol 10540-29-1, Tamoxifen  
 RL: BIOL (Biological study)  
 (bone loss prevention by, after ovariectomy)

L19 ANSWER 17 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1993:254532 HCAPLUS  
 DOCUMENT NUMBER: 118:254532  
 TITLE: Preparation of triphenylethylene derivatives as  
 antitumor agents and for treatment of osteoporosis  
 INVENTOR(S): Kouji, Hiroyuki; Ando, Satoshi  
 PATENT ASSIGNEE(S): Asahi Kasei Kogyo K. K., Japan  
 SOURCE: PCT Int. Appl., 112 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9219585	A1	19921112	WO 1992-JP570	19920430
W: AU, CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
JP 04330043	A2	19921118	JP 1991-124583	19910430
JP 04330071	A2	19921118	JP 1991-124584	19910430
JP 04356447	A2	19921210	JP 1991-156268	19910531
JP 05017424	A2	19930126	JP 1991-189495	19910704
JP 05039250	A2	19930219	JP 1991-219377	19910806
JP 05043522	A2	19930223	JP 1991-226419	19910813
JP 05112511	A2	19930507	JP 1991-296641	19911017
CA 2109426	AA	19921031	CA 1992-2109426	19920430
AU 9217402	A1	19921221	AU 1992-17402	19920430
AU 659157	B2	19950511		
EP 589039	A1	19940330	EP 1992-908856	19920430
R: CH, DE, ES, FR, GB, IT, LI				
PRIORITY APPLN. INFO.:				
			JP 1991-124583	19910430
			JP 1991-124584	19910430
			JP 1991-156268	19910531
			JP 1991-189495	19910704
			JP 1991-219377	19910806
			JP 1991-226419	19910813
			JP 1991-296641	19911017
			WO 1992-JP570	19920430
OTHER SOURCE(S):	MARPAT 118:254532			
GI				



AB Triphenylalkylene derivs. [I; R1 = CH<sub>2</sub>CH(OR<sub>8</sub>)CH<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>, CH(CH<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>; R<sub>6</sub>, R<sub>7</sub> = H, (cyclo)alkyl, or NR<sub>6</sub>R<sub>7</sub> = heterocyclyl optionally contg. heteroatoms, provided that R<sub>6</sub> = R<sub>7</sub> .noteq. H; R<sub>8</sub> = H, alkylcarbonyl; R<sub>2</sub> = (cyclo)alkyl; R<sub>3</sub> = Ph, 3,4-methylenedioxyphenyl, provided that R<sub>3</sub> = Ph, R<sub>1</sub> .noteq. CH<sub>2</sub>CH<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>; R<sub>4</sub> = H, OH, R<sub>9</sub>CO<sub>2</sub>, R<sub>10</sub>CH<sub>2</sub>O, OP(O)(OH)<sub>2</sub>, CH:NOR<sub>11</sub>; R<sub>9</sub> = alkyl; R<sub>10</sub> = alkyl, alkylcarbonyl; R<sub>5</sub> = H, CH:NOR<sub>11</sub>; R<sub>11</sub> = H, alkyl, phenylalkyl, alkoxyalkylalkyl], having strong anti-estrogen activity and useful for the treatment of hormone-dependent breast cancer, are prepd. Thus, olefination of 4,4'-dihydroxybenzophenone with 3,4-methylenedioxypropionophenone in the presence of TiCl<sub>4</sub> and Zn in THF to give 1,1-bis(4-hydroxyphenyl)-2-(3,4-methylenedioxyphenyl)-1-butene followed by conversion into the K salt in 0.5N aq. NaOH and etherification with epibromohydrin in DMF gave 1-[4-(2,3-epoxypropoxy)phenyl]-1-(4-hydroxyphenyl)-2-(3,4-methylenedioxyphenyl)-1-butene which was aminated with 50% aq. Me<sub>2</sub>NH in EtOH to give (E,Z)-I (R<sub>1</sub> = CH<sub>2</sub>CH(OH)CH<sub>2</sub>NMe<sub>2</sub>, R<sub>2</sub> = Et, R<sub>3</sub> = 3,4-methylenedioxyphenyl, R<sub>4</sub> = OH, R<sub>5</sub> = H) (II). II at 1 .mu.g/day i.p. inhibited estradiol-induced uterine wt. increase in rats by 56.6%, vs. 5.8% for tamoxifen.

IT 103545-15-9P 147322-26-7P 147322-27-8P  
 147322-31-4P 147322-32-5P 147322-33-6P  
 147322-40-5P 147322-41-6P 147322-42-7P  
 147322-43-8P 147322-44-9P 147322-45-0P  
 147322-46-1P 147322-53-0P 147322-54-1P  
 147322-57-4P 147322-58-5P 147322-59-6P  
 147322-60-9P 147322-61-0P 147322-64-3P  
 147322-65-4P 147322-66-5P 147322-67-6P  
 147322-68-7P 147322-69-8P 147322-70-1P  
 147322-71-2P 147322-72-3P 147322-73-4P  
 147322-74-5P 147322-75-6P 147322-76-7P  
 147322-83-6P 147322-84-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as antitumor agent and for treatment of  
 osteoporosis)

IT 68684-63-9P 91221-46-4P 147308-12-1P  
 147308-13-2P 147322-98-3P 147322-99-4P  
 147323-02-2P 147323-03-3P 147323-04-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as intermediate for antitumor and anti-osteoporosis  
 triphenylalkylene)

L19 ANSWER 18 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1992:605220 HCAPLUS

DOCUMENT NUMBER: 117:205220  
 TITLE: Treatment of osteoporosis with phosphonates and estrogens  
 INVENTOR(S): McOsker, Jocelyn Elaine  
 PATENT ASSIGNEE(S): Norwich Eaton Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9214474	A1	19920903	WO 1992-US854	19920131
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
CA 2101275	AA	19920827	CA 1992-2101275	19920131
CA 2101275	C	19980804		
AU 9216433	A1	19920915	AU 1992-16433	19920131
AU 664368	B2	19951116		
EP 573604	A1	19931215	EP 1992-908494	19920131
EP 573604	B1	19950315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL				
JP 06505501	T2	19940623	JP 1992-511584	19920131
HU 66429	A2	19941128	HU 1993-2407	19920131
HU 215124	B	19980928		
AT 119777	E	19950415	AT 1992-908494	19920131
ES 2069424	T3	19950501	ES 1992-908494	19920131
CZ 282609	B6	19970813	CZ 1993-1755	19920131
RU 2113848	C1	19980627	RU 1993-54017	19920131
NO 9303044	A	19930826	NO 1993-3044	19930826
PRIORITY APPLN. INFO.:			US 1991-661777 A	19910226
			WO 1992-US854 A	19920131

OTHER SOURCE(S): MARPAT 117:205220

AB Osteoporosis is treated in humans or animals with a bone-active phosphonate, esp. a bisphosphonate or a phosphonoalkylphosphonate [gtoreq.0.1 LED (least ED)/day] and an estrogen (gtoreq.0.2-0.8 LED/day). Thus, a woman with postmenopausal osteoporosis was treated daily for 1 yr with 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid (15 mg in a tablet) and 17.beta.-estradiol (0.03 mg from a transdermal patch).


IT 56-53-1, Diethylstilbestrol 569-57-3, Chlorotrianisene  
 RL: BIOL (Biological study)  
 (osteoporosis treatment with phosphonate deriv. and)

L19 ANSWER 19 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:490313 HCAPLUS  
 DOCUMENT NUMBER: 117:90313  
 TITLE: Preparation of prazosin analogs  
 INVENTOR(S): Pitha, Josef; Kusiak, John W.  
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA  
 SOURCE: U.S., 13 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5110927	A	19920505	US 1987-140744	19871231
OTHER SOURCE(S):		MARPAT 117:90313		
GI				



AB Title compds. I [R = 1-imidazolylcarbonyl, COCH<sub>2</sub>Br, (substituted) cinnamoyl, PhNHC(:S), bicyclo[2.2.2]octa-2,5-dien-2-ylcarbonyl, bicyclo[2.2.2]oct-2-en-2-ylcarbonyl, etc.] were prepd. as antihypertensives. Thus, 1,3-cyclohexadiene underwent Diels-Alder cyclization with HC.tplbond.CCO<sub>2</sub>H to give bicyclo[2.2.2]octa-2,5-diene-2-carboxylic acid. This was converted to the acid chloride then treated with 4-amino-6,7-dimethoxy-2-(piperazin-1-yl)quinazoline to give title compd. I [R = bicyclo[2.2.2]octa-2,5-dien-2-ylcarbonyl] (II). For rats treated with II (0.09 mg/kg i.v.) or prazosin (0.11 mg/kg i.v.), the ones treated with II needed higher doses of phenylephrine to obtain increase in blood pressure.

IT 119809-77-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as antihypertensive)

L19 ANSWER 20 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:463786 HCAPLUS

DOCUMENT NUMBER: 117:63786

TITLE: Bone growth factors and inhibitors of bone resorption for promoting bone formation

INVENTOR(S): Adams, Steven W.; Armstrong, Rosa; Rosen, David

PATENT ASSIGNEE(S): Celtrix Pharmaceuticals, Inc., USA

SOURCE: U.S., 11 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5118667	A	19920602	US 1991-695310	19910503
CA 2102429	AA	19921104	CA 1992-2102429	19920501
WO 9219262	A1	19921112	WO 1992-US3600	19920501
W: AU, CA, JP				
AU 9218913	A1	19921221	AU 1992-18913	19920501
AU 660182	B2	19950615		
JP 06511233	T2	19941215	JP 1992-510956	19920501

EP 514720 A2 19921125 EP 1992-107773 19920508  
EP 514720 A3 19930303  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE  
PRIORITY APPLN. INFO.: US 1991-695310 19910503  
WO 1992-US3600 19920501


AB Bone growth factors are used to stimulate new bone formation when administered with agents that inhibit bone resorption. Treatment of ovariectomized rats with transforming growth factor-.beta. resulted in increased bone formation. This was enhanced by concomitant treatment with estrogen.

IT 10540-29-1, Tamoxifen  
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)  
(bone formation promotion by bone growth factors and, as **bone resorption** inhibitor)

L19 ANSWER 21 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1992:248381 HCAPLUS  
DOCUMENT NUMBER: 116:248381  
TITLE: Tamoxifen prevents bone loss in ovariectomized mice  
AUTHOR(S): Broulik, P. D.  
CORPORATE SOURCE: Fac. Med., Charles Univ., Prague, 128 21, Czech.  
SOURCE: Endocr. Regul. (1991), 25(4), 217-19  
CODEN: EREG3  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Bone d. and mineral content of the femora were decreased in ovariectomized mice compared with intact control animals. Tamoxifen treated ovariectomized mice did not develop a decrease either in the bone d. or in calcium and phosphate content of the femora which were obsd. in ovariectomized mice. In addn., the wt. of uterus in tamoxifen-treated ovariectomized mice was the same as in intact controls. Thus, tamoxifen administered in vivo prevented the loss of bone mineral and uterus wt. in ovariectomized mice and thus showing true estrogen like activity.  
IT 10540-29-1, Tamoxifen  
RL: BIOL (Biological study)  
(**bone loss** from overiectomy prevention by)

L19 ANSWER 22 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1992:83664 HCAPLUS  
DOCUMENT NUMBER: 116:83664  
TITLE: Preparation of 5,6,7,8-tetrahydro-4H-thiazolo[5,4-b]azepine derivatives as antihypertensives  
INVENTOR(S): Aono, Tetsuya; Shimamoto, Norio  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03206042	A2	19910909	JP 1990-833	19900106
OTHER SOURCE(S):	MARPAT 116:83664			
GI				



AB The title compds. [I; R1 = H, (un)substituted aliph., acyl or sulfonyl; R2 = H, (un)substituted arom. or aliph.] are prepd. as K channel opener. Thus, 14.8 g 1,1'-carbonyldiimidazole was added to a soln. of 12 g 2,6-F2C6H3CO2H in THF and thereto after stirring 15 min at room temp. 9.73 g 3-amino-.epsilon.-caprolactam was added and the mixt. was stirred 5 h at room temp. to give 13.5 g 3-(2,6-difluorobenzoylamino)-.epsilon.-caprolactam which (8.96 g) was refluxed 24 h, with 8.96 g P4S10 in pyridine to give 23.8% I (R1 = H, R2 = 2,6-F2C6H3) (II). II and I [R1 = H, R2 = (Z)-4-Et2NC6H4CH:CH] (III) in vitro inhibited 8 and 100%, resp., rat aorta contraction induced by Et3NCl and BaCl2 and gave no inhibition of the one induced by 80 mM KCl. II and III at 1 mg/kg i.v. lowered 49 and 46%, resp. the blood pressure of rats. A total of 175 I were prepd.

IT 128068-06-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and sulfuration-cyclization of, **antihypertensive**  
tetrahydrothiazoloazepine deriv. from)

IT 128068-59-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as **antihypertensive**)

L19 ANSWER 23 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:76566 HCAPLUS

DOCUMENT NUMBER: 116:76566

TITLE:

A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat  
Kalu, D. N.; Salerno, E.; Liu, C. C.; Echon, R.; Ray, M.; Garza-Zapata, M.; Hollis, B. W.

AUTHOR(S):

CORPORATE SOURCE:

Health Sci. Cent., Univ. Texas, San Antonio, TX, 78284-7756, USA

SOURCE:

Bone Miner. (1991), 15(2), 109-23

CODEN: BOMIET; ISSN: 0169-6009

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB This study was undertaken to examine the sep. and combined effects of tamoxifen (T), estrogen (E2), and progesterone (P) treatment on ovariectomized (Ooph) rats. The animals were treated for 40 days. Ovariectomy reduced cancellous bone vol. at the proximal tibia by 50%. Estradiol treatment completely prevented the bone loss and further increased bone vol. 77% over the level for the control group. Tamoxifen also prevented the ovariectomy-induced bone loss, but reduced the increase in cancellous bone induced by estradiol. In the ovariectomized rats, cancellous bone apposition rate increased 23%. This increase was suppressed 63% by estradiol, and only 18% by tamoxifen. Tamoxifen suppressed the inhibitory effect of estradiol on cancellous bone apposition rate. In contrast, the effect of progesterone treatment was only marginal. These findings indicate that the action of tamoxifen on bone is influenced by the ambient level of circulating estradiol, such that in estrogen deficiency, tamoxifen has a weak estrogen against action on bone, and in the presence of estrogen it has antiestrogen actions, with the dose

level and mode of administration employed. These conclusions have implications for the use of tamoxifen in the treatment of pre- and postmenopausal women.

IT 10540-29-1, Tamoxifen

RL: BIOL (Biological study)

(bone loss inhibition by, estradiol effect on)

L19 ANSWER 24 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1991:536564 HCAPLUS

DOCUMENT NUMBER: 115:136564

TITLE: Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines

AUTHOR(S): Francis, John E.; Webb, Randy L.; Ghai, Geetha R.; Hutchison, Alan J.; Moskal, Michael A.; DeJesus, Reynalda; Yokoyama, Rina; Rovinski, Stephen L.; Contardo, Nicolina; et al.

CORPORATE SOURCE: Pharm. Div., Ciba-Geigy Corp., Summit, NJ, 07901, USA


SOURCE: J. Med. Chem. (1991), 34(8), 2570-9

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A wide variety of 2-substituted aminoadenosines were prepd. for comparison with the moderately A2 receptor selective adenosine agonist 2-anilinoadenosine. High selectivity combined with significant affinity at the A2 receptor in rat membranes was obsd. for those amines bearing a two-carbon chain to which was attached an aryl, heteroaryl, or alicyclic moiety. 2-(2-Phenethylamino)adenosine, a 14-fold A2 selective compd., was modified by introduction of a variety of substituents in the benzene ring and the side chain. Some of these changes led to improved A2 affinity and increased selectivity. Replacement of the Ph moiety by cyclohexenyl produced a 210-fold selective agonist I (R = cyclohexyl) whereas the cyclohexyl analog I (R = 1-cyclohexen-1-yl) was 530-fold selective at the A2 site. These compds. showed hypotensive activity in rat models over a range of doses without the bradycardia obsd. with less selective agonists.

IT 124498-89-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn., adenosine receptor agonist, and antihypertensive activity of)

L19 ANSWER 25 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1990:545496 HCAPLUS

DOCUMENT NUMBER: 113:145496  
TITLE: The relation between serum growth hormone and estradiol levels and osteoporosis in postmenopausal women  
AUTHOR(S): Li, Guohua; Zeng, Meizhen  
CORPORATE SOURCE: Coll. Med., Jinan Univ., Guangzhou, Peop. Rep. China  
SOURCE: Zhonghua Yixue Zazhi (1990), 70(1), 16-19  
CODEN: CHHTAT; ISSN: 0300-2578  
DOCUMENT TYPE: Journal  
LANGUAGE: Chinese  
AB Serum growth hormone (GH), estradiol (E2), FSH, LH, alk. phosphatase, and Ca levels, bone mass, and urinary Ca/creatinine ratio were detd. in postmenopausal women and compared with those in fertile women. The postmenopausal women had reduced serum levels of GH and E2 and bone mass and increased levels of serum FSH, LH, and alk. phosphatase and urinary Ca/creatinine ratio. The serum level of GH increased, whereas that of FSH, LH, and alk. phosphatase and urinary Ca/creatinine ratio were all decreased after di-Et stilbestrol treatment. Apparently, there is bone loss in early postmenopause and estrogen replacement therapy is necessary in postmenopausal women.  
IT 56-53-1, Diethyl stilbestrol  
RL: BIOL (Biological study)  
(alk. phosphatase and gonadotropins and growth hormone of blood serum and calcium of urine response to, in postmenopausal women, **osteoporosis** in relation to)

L19 ANSWER 26 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1990:526731 HCAPLUS  
DOCUMENT NUMBER: 113:126731  
TITLE: Hypotensive effects on spontaneously hypertensive rats and antifungal activity on various species of Fusarium oxysporum of diethylstilbestrol-related compounds  
AUTHOR(S): Inamori, Yoshihiko; Ogawa, Masafumi; Amino, Hisako; Tsuboi, Mariko; Yamaguchi, Satomi; Tsujibo, Hiroshi; Takemura, Shoji  
CORPORATE SOURCE: Osaka Univ. Pharm. Sci., Matsubara, 580, Japan  
SOURCE: Chem. Pharm. Bull. (1990), 38(7), 2045-6  
CODEN: CPBTAL; ISSN: 0009-2363  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 56-53-1, Diethylstilbestrol  
RL: BIOL (Biological study)  
(antifungal and **antihypertensive** activities of)

L19 ANSWER 27 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1990:400561 HCAPLUS  
DOCUMENT NUMBER: 113:561  
TITLE: Antiestrogens and their use in treatment of menopause and osteoporosis  
INVENTOR(S): Young, Ronald L.  
PATENT ASSIGNEE(S): BCM Technologies, Inc., USA  
SOURCE: U.S., 10 pp. Cont.-in-part of U.S. 4,729,999.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4894373	A	19900116	US 1988-143081	19880112
US 4729999	A	19880308	US 1984-660510	19841012
JP 61178917	A2	19860811	JP 1985-226022	19851012
JP 06080017	B4	19941012		

PRIORITY APPLN. INFO.: US 1984-660510 19841012

OTHER SOURCE(S): MARPAT 113:561

IT 50-41-9 911-45-5, Clomiphene 5863-35-4  
 10448-84-7 10540-29-1, Tamoxifen 54965-24-1  
 56287-31-1, CI-680

RL: BIOL (Biological study)  
 (estrogen deficiency in menopause and osteoporosis treatment with)

L19 ANSWER 28 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1990:119353 HCAPLUS

DOCUMENT NUMBER: 112:119353

TITLE: Preparation of 2-substituted adenosine derivatives as antihypertensive and antiatherosclerotic agents and pharmaceutical compositions containing them

INVENTOR(S): Hutchison, Alan J.; Francis, John E.

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 34 pp.  
 CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 323807	A2	19890712	EP 1988-810900	19881229
EP 323807	A3	19900620		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5034381	A	19910723	US 1988-193968	19880513
NO 8805821	A	19890710	NO 1988-5821	19881230
NO 169843	B	19920504		
NO 169843	C	19920812		
FI 8900028	A	19890708	FI 1989-28	19890104
FI 90430	B	19931029		
FI 90430	C	19940210		
HU 48904	A2	19890728	HU 1989-33	19890105
HU 202550	B	19910328		
ZA 8900084	A	19890830	ZA 1989-84	19890105
DD 283402	A5	19901010	DD 1989-324859	19890105
CA 1325209	A1	19931214	CA 1989-587534	19890105
DK 8900050	A	19890708	DK 1989-50	19890106
AU 8927767	A1	19890713	AU 1989-27767	19890106
AU 618055	B2	19911212		
JP 01265100	A2	19891023	JP 1989-590	19890106

PRIORITY APPLN. INFO.: US 1988-142055 19880107  
 US 1988-193968 19880513

IT 124499-27-0P 124499-28-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction of, in prepn. of antihypertensives and antiatherosclerotics)

IT 124498-89-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as **antihypertensive** and antiatherosclerotic)

L19 ANSWER 29 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1989:508829 HCAPLUS  
 DOCUMENT NUMBER: 111:108829  
 TITLE: Effects of two inhibitors of anion transport on bone  
 resorption in organ culture  
 AUTHOR(S): Klein-Nulend, Jenneke; Raisz, Lawrence G.  
 CORPORATE SOURCE: Health Cent., Univ. Connecticut, Farmington, CT,  
 06032, USA  
 SOURCE: Endocrinology (Baltimore) (1989), 125(2), 1019-24  
 CODEN: ENDOAO; ISSN: 0013-7227  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 51023-76-8, SITS 53005-05-3, DIDS

RL: BIOL (Biological study)  
 (**bone resorption** inhibition by, calcium and  
 parathormone in)

L19 ANSWER 30 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1988:622782 HCAPLUS  
 DOCUMENT NUMBER: 109:222782  
 TITLE: Neonatal diethylstilbestrol alters blood pressure and  
 CNS drinking response in SHR and WKY rats  
 AUTHOR(S): Lamartiniere, C. A.; Pearson, A. T.; Rockhold, R. W.  
 CORPORATE SOURCE: Dep. Environ. Health Sci., Univ. Alabama, Birmingham,  
 AL, 35294, USA  
 SOURCE: Clin. Exp. Hypertens., Part A (1988), A10(5), 843-57  
 CODEN: CEHADM; ISSN: 0730-0077  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 56-53-1, Diethylstilbestrol

RL: BIOL (Biological study)  
 (**blood pressure** and water drinking responses to  
 neonatal administration of)

L19 ANSWER 31 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1988:529008 HCAPLUS  
 DOCUMENT NUMBER: 109:129008  
 TITLE: Preparation of angiotensin II receptor-blocking  
 (phenylalkyl)imidazoles  
 INVENTOR(S): Carini, David John; Duncia, John Jonas Vytautas  
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA  
 SOURCE: Eur. Pat. Appl., 314 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 253310	A2	19880120	EP 1987-109919	19870709
EP 253310	A3	19900829		
EP 253310	B1	19941026		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1334092	A1	19950124	CA 1987-540399	19870623

NO 8702863	A	19880112	NO 1987-2863	19870709
NO 176049	B	19941017		
NO 176049	C	19950125		
ES 2063734	T3	19950116	ES 1987-109919	19870709
DK 8703596	A	19880112	DK 1987-3596	19870710
FI 8703071	A	19880112	FI 1987-3071	19870710
FI 96025	B	19960115		
FI 96025	C	19960425		
AU 8775596	A1	19880121	AU 1987-75596	19870710
AU 599396	B2	19900719		
JP 63023868	A2	19880201	JP 1987-171328	19870710
JP 05029351	B4	19930430		
HU 45976	A2	19880928	HU 1987-3174	19870710
ZA 8705052	A	19890329	ZA 1987-5052	19870710
SU 1694062	A3	19911123	SU 1987-4203085	19870710
IL 83153	A1	19911215	IL 1987-83153	19870710
US 5128355	A	19920707	US 1989-435869	19891113
US 5153197	A	19921006	US 1989-436165	19891113
US 5155118	A	19921013	US 1989-436281	19891113
PRIORITY APPLN. INFO.:			US 1986-884920	A 19860711
			US 1987-50341	A 19870522
			US 1988-142580	B2 19880107
			US 1988-279194	A3 19881206

OTHER SOURCE(S): MARPAT 109:129008

IT 114773-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and reaction of, in prepn. of **antihypertensives**)

IT 114799-60-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as **antihypertensive**)

L19 ANSWER 32 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1988:473432 HCAPLUS

DOCUMENT NUMBER: 109:73432

TITLE: Preparation of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acids and analogs as antihypertensives

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 58 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62240683	A2	19871021	JP 1987-76534	19870331
JP 2506105	B2	19960612		
US 4812462	A	19890314	US 1986-847067	19860401
EP 245637	A1	19871119	EP 1987-104736	19870331
EP 245637	B1	19911016		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 68495	E	19911115	AT 1987-104736	19870331
ES 2038613	T3	19930801	ES 1987-104736	19870331
US 4816463	A	19890328	US 1987-35521	19870407
JP 08208652	A2	19960813	JP 1995-313683	19951108

JP 2648793 B2 19970903  
 PRIORITY APPLN. INFO.: US 1986-847067 19860401  
 EP 1987-104736 19870331  
 OTHER SOURCE(S): CASREACT 109:73432

IT 114787-47-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of, as **antihypertensive**)

L19 ANSWER 33 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1988:454470 HCAPLUS

DOCUMENT NUMBER: 109:54470

TITLE: Aminoalkyl derivatives of cis- and trans-stilbenes, useful in the treatment of angina and hypertension, and a process for their preparation

INVENTOR(S): Carson, John Robert

PATENT ASSIGNEE(S): McNeilab, Inc., USA

SOURCE: Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 250254	A1	19871223	EP 1987-305453	19870619
EP 250254	B1	19910619		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 63022547	A2	19880130	JP 1987-150356	19870618
ZA 8704448	A	19890222	ZA 1987-4448	19870618
DK 8703155	A	19871221	DK 1987-3155	19870619
AU 8774534	A1	19871224	AU 1987-74534	19870619
AT 64591	E	19910715	AT 1987-305453	19870619
AU 9176375	A1	19910808	AU 1991-76375	19910503
PRIORITY APPLN. INFO.:			US 1986-876628	19860620
			EP 1987-305453	19870619

IT 115198-25-9P 115198-26-0P 115198-27-1P  
 115198-28-2P 115198-29-3P 115198-30-6P  
 115198-31-7P 115198-32-8P 115198-33-9P  
 115198-34-0P 115198-35-1P 115198-36-2P  
 115198-37-3P 115198-38-4P 115198-39-5P  
 115198-40-8P 115198-41-9P 115198-42-0P  
 115198-43-1P 115198-44-2P 115198-45-3P  
 115198-46-4P 115198-47-5P 115198-48-6P  
 115198-49-7P 115198-50-0P 115198-51-1P  
 115198-52-2P 115198-53-3P 115198-54-4P  
 115198-55-5P 115216-66-5P 115216-67-6P  
 115466-00-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as antianginal and **antihypertensive**)

L19 ANSWER 34 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1988:143689 HCAPLUS

DOCUMENT NUMBER: 108:143689

TITLE: Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats

AUTHOR(S): Turner, Russell T.; Wakley, Glenn K.; Hannon, Kathleen

- CORPORATE SOURCE: S.; Bell, Norman H.  
Dep. Physiol. Pharmacol., Loma Linda Univ., Loma  
Linda, CA, 92354, USA
- SOURCE: Endocrinology (Baltimore) (1988), 122(3), 1146-50  
CODEN: ENDOAO; ISSN: 0013-7227
- DOCUMENT TYPE: Journal
- LANGUAGE: English
- IT 10540-29-1, Tamoxifen  
RL: BIOL (Biological study)  
(osteoclast-mediated **bone resorption** inhibition by)
- L19 ANSWER 35 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1988:107682 HCAPLUS  
DOCUMENT NUMBER: 108:107682  
TITLE: Effects of vanadate on vascular smooth muscles of WKY  
and SHRSP  
AUTHOR(S): Sunano, Satoru; Shimada, Tomoko; Shimamura, Keiichi  
CORPORATE SOURCE: Inst. Hypertension, Kinki Univ., Osaka, Japan  
SOURCE: Jpn. Heart J. (1987), 28(5), 765-81  
CODEN: JHEJAR; ISSN: 0021-4868  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 53005-05-3, DIDS  
RL: BIOL (Biological study)  
(vanadate-induced contraction of vascular smooth muscle response to,  
**hypertensive** strain in relation to)
- L19 ANSWER 36 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1988:69162 HCAPLUS  
DOCUMENT NUMBER: 108:69162  
TITLE: Effects of anti-estrogens on bone in castrated and  
intact female rats  
AUTHOR(S): Jordan, V. Craig; Phelps, Erik; Lindgren, J. Urban  
CORPORATE SOURCE: Clin. Cancer Cent., Univ. Wisconsin, Madison, WI,  
53792, USA  
SOURCE: Breast Cancer Res. Treat. (1987), 10(1), 31-5  
CODEN: BCTRD6; ISSN: 0167-6806  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 10540-29-1, Tamoxifen  
RL: BIOL (Biological study)  
(**bone loss** inhibition by, after ovariectomy)
- L19 ANSWER 37 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1986:583914 HCAPLUS  
DOCUMENT NUMBER: 105:183914  
TITLE: Inhibition of cholesterol and fatty acid synthesis in  
rats by an estrogen antagonist both in isolated  
hepatocytes and in vivo  
AUTHOR(S): McCune, Sylvia A.; Rimmell, Frank; Hoversland, Roger  
C.; Jurin, Richard R.  
CORPORATE SOURCE: Chicago Med. Sch., Univ. Health Sci., North Chicago,  
IL, 60064, USA  
SOURCE: Biochem. Soc. Trans. (1986), 14(6), 1198  
CODEN: BCSTB5; ISSN: 0300-5127  
DOCUMENT TYPE: Journal  
LANGUAGE: English
- L19 ANSWER 38 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:207168 HCAPLUS  
 DOCUMENT NUMBER: 104:207168  
 TITLE: 1,4-Dihydropyridine derivatives and pharmaceutical compositions comprising them  
 INVENTOR(S): Kutsuma, Teruo; Ikawa, Hiroshi; Sato, Yoshiaki  
 PATENT ASSIGNEE(S): Fujirebio, Inc., Japan  
 SOURCE: Eur. Pat. Appl., 67 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 161877	A2	19851121	EP 1985-303141	19850502
EP 161877	A3	19870729		
EP 161877	B1	19910529		
R: CH, DE, FR, GB, IT, LI, NL				
JP 60233058	A2	19851119	JP 1984-88411	19840504
JP 03014307	B4	19910226		
JP 61007255	A2	19860113	JP 1984-125379	19840620
JP 06029245	B4	19940420		
US 4672068	A	19870609	US 1985-727692	19850426
JP 01025758	A2	19890127	JP 1988-169086	19880708
PRIORITY APPLN. INFO.:				
			JP 1984-88411	19840504
			JP 1984-125379	19840620

OTHER SOURCE(S): CASREACT 104:207168

IT 102106-41-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of, as antihypertensive)

L19 ANSWER 39 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:129927 HCAPLUS  
 DOCUMENT NUMBER: 104:129927  
 TITLE: Piperazine derivatives  
 INVENTOR(S): Komoto, Teruo; Sato, Susumu; Ogawa, Yoichiro; Isomae, Kazuo; Katori, Tatsuhiko  
 PATENT ASSIGNEE(S): S. S. Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60204763	A2	19851016	JP 1984-61517	19840329
IT 100982-50-1P				
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as vasodilator and antihypertensive)				

L19 ANSWER 40 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:45971 HCAPLUS  
 DOCUMENT NUMBER: 104:45971  
 TITLE: Effects of the antiestrogens tamoxifen and clomiphene

- on bone resorption in vitro  
 AUTHOR(S): Stewart, Pamela J.; Stern, Paula H.  
 CORPORATE SOURCE: Med. Dent. Sch., Northwest. Univ., Chicago, IL, 60611, USA  
 SOURCE: Endocrinology (Baltimore) (1986), 118(1), 125-31  
 CODEN: ENDOAO; ISSN: 0013-7227  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 911-45-5 10540-29-1  
 RL: BIOL (Biological study)  
 (bone resorption inhibition by)
- L19 ANSWER 41 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1985:426532 HCAPLUS  
 DOCUMENT NUMBER: 103:26532  
 TITLE: Lead exposure and changes in the renin-angiotensin-aldosterone system in man  
 AUTHOR(S): Campbell, B. C.; Meredith, P. A.; Scott, J. J. C.  
 CORPORATE SOURCE: Stobhill Gen. Hosp., Univ. Glasgow, Glasgow, G21 3UW, UK  
 SOURCE: Toxicol. Lett. (1985), 25(1), 25-32  
 CODEN: TOLED5; ISSN: 0378-4274  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English
- L19 ANSWER 42 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1983:46935 HCAPLUS  
 DOCUMENT NUMBER: 98:46935  
 TITLE: Chloroquine, hydroxystilbamidine, and dapsone inhibit resorption of fetal rat bone in organ culture  
 AUTHOR(S): Eilon, Gabriel; Raisz, Lawrence G.  
 CORPORATE SOURCE: Health Cent., Univ. Connecticut, Farmington, CT, 06032, USA  
 SOURCE: Calcif. Tissue Int. (1982), 34(5), 506-9  
 CODEN: CTINDZ; ISSN: 0171-967X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 495-99-8  
 RL: BIOL (Biological study)  
 (bone resorption inhibition by)
- L19 ANSWER 43 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1980:561754 HCAPLUS  
 DOCUMENT NUMBER: 93:161754  
 TITLE: Vascular action of high dose estrogen in rats  
 AUTHOR(S): Kondo, Kazuoki; Okuno, Tetsuji; Eguchi, Toyohisa; Yasui, Toshiyuki; Suzuki, Hiromichi; Nagahama, Shusaku; Saruta, Takao  
 CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan  
 SOURCE: Endocrinol. Jpn. (1980), 27(3), 307-13  
 CODEN: ECJPAE; ISSN: 0013-7219  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 522-40-7  
 RL: BIOL (Biological study)  
 (artery contraction and blood pressure response to)
- L19 ANSWER 44 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1980:195361 HCAPLUS

- DOCUMENT NUMBER: 92:195361  
 TITLE: Influence of adult age on the skeletal response to phosphate and estrogen in rats  
 AUTHOR(S): Draper, H. H.; Bell, R. Raines; Shin, Keun S.  
 CORPORATE SOURCE: Dep. Food Sci., Univ. Illinois, Urbana, IL, 61801, USA  
 SOURCE: J. Nutr. (1980), 110(4), 778-83  
 CODEN: JONUAI; ISSN: 0022-3166  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 56-53-1  
 RL: BIOL (Biological study)  
 (bone resorption response to, in senescence,  
 dietary phosphate in relation to)
- L19 ANSWER 45 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1980:158238 HCAPLUS  
 DOCUMENT NUMBER: 92:158238  
 TITLE: Hypertension and sex hormones  
 AUTHOR(S): Saruda, Akio  
 CORPORATE SOURCE: Med. Sch., Keio Univ., Tokyo, Japan  
 SOURCE: Kawaguchiko Kanferansu (1978), 12(Koketsuatsu to Horumon), 149-64  
 CODEN: KAKNDY  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Japanese  
 IT 56-53-1  
 RL: BIOL (Biological study)  
 (blood pressure and angiotensin-renin system  
 response to, contraceptive activity in relation to)
- L19 ANSWER 46 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1979:16821 HCAPLUS  
 DOCUMENT NUMBER: 90:16821  
 TITLE: Effect of estrogen upon the juxtaglomerular apparatus and the renin-angiotensin system in rats  
 AUTHOR(S): Kondo, Kazuoki; Misumi, Jiro; Nakamura, Ryuichi; Saito, Ikuo; Saruta, Takao  
 CORPORATE SOURCE: Dep. Intern. Med., Univ. Keio Sch. Med., Tokyo, Japan  
 SOURCE: Tohoku J. Exp. Med. (1978), 126(3), 267-72  
 CODEN: TJEMAO; ISSN: 0040-8727  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English
- L19 ANSWER 47 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1979:16785 HCAPLUS  
 DOCUMENT NUMBER: 90:16785  
 TITLE: Effects of estrogenic hormones on uteroplacental hemodynamics and progesterone production in the sheep  
 AUTHOR(S): Assali, N. S.; Clark, K. E.; Zugaib, M.; Brinkman, C. R., III; Nuwayhid, B.  
 CORPORATE SOURCE: Sch. Med., Univ. California, Los Angeles, Calif., USA  
 SOURCE: Int. J. Fertil. (1978), 23(3), 219-23  
 CODEN: INJFA3; ISSN: 0020-725X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English
- L19 ANSWER 48 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1979:16671 HCAPLUS  
 DOCUMENT NUMBER: 90:16671

TITLE: Relation of hemodynamics to the incidence of diethylstilbestrol-induced aortic ruptures in hypertensive and hypotensive lines of turkeys  
 AUTHOR(S): Simpson, Charles F.  
 CORPORATE SOURCE: Coll. Vet. Med., Univ. Florida, Gainesville, Fla., USA  
 SOURCE: Atherosclerosis (Shannon, Irel.) (1978), 30(4), 249-54  
 CODEN: ATHSBL; ISSN: 0021-9150  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

L19 ANSWER 49 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1976:428964 HCAPLUS  
 DOCUMENT NUMBER: 85:28964  
 TITLE: Changes in blood pressure and norepinephrine concentration following administration of estrogens to genetically hypertensive and normotensive rats  
 AUTHOR(S): Lew, G. M.  
 CORPORATE SOURCE: Dep. Anat., Michigan State Univ., East Lansing, Mich., USA  
 SOURCE: Gen. Pharmacol. (1975), 6(2-3), 121-5  
 CODEN: GEPHDP  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 56-53-1  
 RL: BIOL (Biological study)  
 (norepinephrine of adrenal gland and heart response to, in hypertension)

L19 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1975:526645 HCAPLUS  
 DOCUMENT NUMBER: 83:126645  
 TITLE: Estrogen hypertension in rats  
 AUTHOR(S): Saruta, T.; Nakamura, R.; Saito, I.; Kondo, K.; Matuki, S.  
 CORPORATE SOURCE: Sch. Med., Univ. Keio, Tokyo, Japan  
 SOURCE: Clin. Sci. Mol. Med. (1975), 48(5), 457-60  
 CODEN: CSMMDA  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 316-23-4  
 RL: BIOL (Biological study)  
 (hypertension from, plasma renin system in relation to)

L19 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1975:81082 HCAPLUS  
 DOCUMENT NUMBER: 82:81082  
 TITLE: Effect of estrogens and gestagens on exchangeable sodium  
 AUTHOR(S): Crane, Milton G.; Harris, J. J.  
 CORPORATE SOURCE: Dep. Intern. Med., Loma Linda Univ., Loma Linda, Calif., USA  
 SOURCE: Oral Contracept. High Blood Pressure, Proc. Symp. (1974), Meeting Date 1973, 159-69. Editor(s): Fregley, Melvin J; Fregley, Marilyn S. Dolphin Press: Gainesville, Fla.  
 CODEN: 29MKAF  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English

L19 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1973:522020 HCAPLUS  
 DOCUMENT NUMBER: 79:122020  
 TITLE: Mechanism of estrogen hypertension  
 AUTHOR(S): Saruta, Takao; Ozawa, Yukio; Asano, Seiichi  
 CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, Japan  
 SOURCE: Jap. Circ. J. (1972), 36(6), 611-16  
 CODEN: JCIRA2  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 316-23-4

RL: BIOL (Biological study)  
 (hypertension from, renin-angiotensin system in relation to)

L19 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1970:421858 HCAPLUS  
 DOCUMENT NUMBER: 73:21858  
 TITLE: Effects of estrogens on pressor responses to  
 angiotensin and renin  
 AUTHOR(S): Nasjletti, Alberto; Matsunaga, Masato; Masson, Georges  
 M. C.  
 CORPORATE SOURCE: Res. Div., Cleveland Clin. Found., Cleveland, Ohio,  
 USA  
 SOURCE: Proc. Soc. Exp. Biol. Med. (1970), 133(2), 407-9  
 CODEN: PSEBAA  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 56-53-1

RL: BIOL (Biological study)  
 (angiotensin and renin effect on blood pressure in  
 response to)

L19 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1970:97102 HCAPLUS  
 DOCUMENT NUMBER: 72:97102  
 TITLE: Modifications of the serum proteins and calcium, and  
 of bone structure, in growing chickens treated with  
 diethylstilbestrol and thyroxine  
 AUTHOR(S): Ballarini, Giovanni; Orlandini, I.; Ferrari, Angela  
 CORPORATE SOURCE: Ist. Clin. Med. Vet., Univ. Parma, Parma, Italy  
 SOURCE: Veterinaria (Milan) (1969), 18(5), 291-308  
 CODEN: VETEAS  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Italian

IT 56-53-1

RL: BIOL (Biological study)  
 (calcium and globulins of blood serum in response to,  
 osteoporosis induction in relation to)

L19 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1970:87663 HCAPLUS  
 DOCUMENT NUMBER: 72:87663  
 TITLE: Aortic rupture, body weight, and blood pressure in the  
 turkey as influenced by strain, dietary fat,  
 beta-aminopropionitrile fumarate, and  
 diethylstilbestrol  
 AUTHOR(S): Krista, L. M.; Waibel, P. E.; Sautter, J. H.;  
 Shoffner, R. N.  
 CORPORATE SOURCE: Dep. of Anim. Sci., Univ. of Minnesota, St. Paul,

SOURCE: Minn., USA  
Poultry Sci. (1969), 48(6), 1954-60  
CODEN: POSCAL  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 56-53-1

RL: BIOL (Biological study)  
(aortic rupture and **blood pressure** of turkeys in  
response to)

L19 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1967:418252 HCAPLUS  
DOCUMENT NUMBER: 67:18252  
TITLE: Estrogens and postmenopausal osteoporosis  
AUTHOR(S): Strandjord, Nels M.; Lanzl, Lawrence H.  
CORPORATE SOURCE: Univ. of Chicago, Chicago, Ill., USA  
SOURCE: NASA [Spec. Publ.] SP (1965), No. 64, 163-7  
CODEN: NSSPAW  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 56-53-1

RL: BIOL (Biological study)  
(in **osteoporosis** (postmenopausal) prevention)

=>

=>

=> select hit rn 119 1-56  
SELECT IS APPROXIMATELY 46% COMPLETE  
SELECT IS APPROXIMATELY 55% COMPLETE  
COMMAND INTERRUPTED

=>

=>

=> select hit rn 119 1-56  
COMMAND INTERRUPTED  
REENTER FILE 'HCAPLUS'  
AND TRY AGAIN, OR ENTER '?' FOR MORE INFORMATION.

=> fil hcaplus  
FILE 'HCAPLUS' ENTERED AT 10:09:09 ON 19 NOV 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 Nov 2001 VOL 135 ISS 22  
FILE LAST UPDATED: 18 Nov 2001 (20011118/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

```
=> select hit rn 119 1-56
SELECT IS APPROXIMATELY 41% COMPLETE
SELECT IS APPROXIMATELY 44% COMPLETE
SELECT IS APPROXIMATELY 48% COMPLETE
SELECT IS APPROXIMATELY 50% COMPLETE
SELECT IS APPROXIMATELY 51% COMPLETE
SELECT IS APPROXIMATELY 57% COMPLETE
SELECT IS APPROXIMATELY 58% COMPLETE
SELECT IS APPROXIMATELY 69% COMPLETE
E18 THROUGH E136 ASSIGNED
```

```
=> fil reg
COST DISPLAY IS INCOMPLETE
```

	QUANTITY @	RATE	ESTIMATED COST
			U.S. DOLLARS
YOUR TOTAL SESSION COSTS ARE	0.99		427.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		SINCE FILE	TOTAL
CA SUBSCRIBER PRICE		ENTRY	SESSION
		-14.70	-20.58

FILE 'REGISTRY' ENTERED AT 10:28:51 ON 19 NOV 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5  
 DICTIONARY FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

```
=> d his 120
```

(FILE 'HCAPLUS' ENTERED AT 09:57:22 ON 19 NOV 2001)

FILE 'HCAPLUS' ENTERED AT 10:09:09 ON 19 NOV 2001  
 SELECT HIT RN L19 1-56

FILE 'REGISTRY' ENTERED AT 10:28:51 ON 19 NOV 2001  
L20 119 S E18-E136

=>

=>

=> d reg l20 tot

1	RN	209684-38-8	REGISTRY
2	RN	209684-35-5	REGISTRY
3	RN	209684-33-3	REGISTRY
4	RN	209684-31-1	REGISTRY
5	RN	209684-29-7	REGISTRY
6	RN	209684-27-5	REGISTRY
7	RN	209684-24-2	REGISTRY
8	RN	209684-21-9	REGISTRY
9	RN	165813-04-7	REGISTRY
10	RN	165813-03-6	REGISTRY
11	RN	165813-02-5	REGISTRY
12	RN	165813-01-4	REGISTRY
13	RN	147323-04-4	REGISTRY
14	RN	147323-03-3	REGISTRY
15	RN	147323-02-2	REGISTRY
16	RN	147322-99-4	REGISTRY
17	RN	147322-98-3	REGISTRY
18	RN	147322-84-7	REGISTRY
19	RN	147322-83-6	REGISTRY
20	RN	147322-76-7	REGISTRY
21	RN	147322-75-6	REGISTRY
22	RN	147322-74-5	REGISTRY
23	RN	147322-73-4	REGISTRY
24	RN	147322-72-3	REGISTRY
25	RN	147322-71-2	REGISTRY
26	RN	147322-70-1	REGISTRY
27	RN	147322-69-8	REGISTRY
28	RN	147322-68-7	REGISTRY
29	RN	147322-67-6	REGISTRY
30	RN	147322-66-5	REGISTRY
31	RN	147322-65-4	REGISTRY
32	RN	147322-64-3	REGISTRY
33	RN	147322-61-0	REGISTRY
34	RN	147322-60-9	REGISTRY
35	RN	147322-59-6	REGISTRY
36	RN	147322-58-5	REGISTRY
37	RN	147322-57-4	REGISTRY
38	RN	147322-54-1	REGISTRY
39	RN	147322-53-0	REGISTRY
40	RN	147322-46-1	REGISTRY
41	RN	147322-45-0	REGISTRY
42	RN	147322-44-9	REGISTRY
43	RN	147322-43-8	REGISTRY
44	RN	147322-42-7	REGISTRY
45	RN	147322-41-6	REGISTRY
46	RN	147322-40-5	REGISTRY
47	RN	147322-33-6	REGISTRY
48	RN	147322-32-5	REGISTRY
49	RN	147322-31-4	REGISTRY
50	RN	147322-27-8	REGISTRY
51	RN	147322-26-7	REGISTRY

52	RN	147308-13-2	REGISTRY
53	RN	147308-12-1	REGISTRY
54	RN	128068-59-7	REGISTRY
55	RN	128068-06-4	REGISTRY
56	RN	124499-28-1	REGISTRY
57	RN	124499-27-0	REGISTRY
58	RN	124498-89-1	REGISTRY
59	RN	119809-77-7	REGISTRY
60	RN	116057-75-1	REGISTRY
61	RN	115466-00-7	REGISTRY
62	RN	115216-67-6	REGISTRY
63	RN	115216-66-5	REGISTRY
64	RN	115198-55-5	REGISTRY
65	RN	115198-54-4	REGISTRY
66	RN	115198-53-3	REGISTRY
67	RN	115198-52-2	REGISTRY
68	RN	115198-51-1	REGISTRY
69	RN	115198-50-0	REGISTRY
70	RN	115198-49-7	REGISTRY
71	RN	115198-48-6	REGISTRY
72	RN	115198-47-5	REGISTRY
73	RN	115198-46-4	REGISTRY
74	RN	115198-45-3	REGISTRY
75	RN	115198-44-2	REGISTRY
76	RN	115198-43-1	REGISTRY
77	RN	115198-42-0	REGISTRY
78	RN	115198-41-9	REGISTRY
79	RN	115198-40-8	REGISTRY
80	RN	115198-39-5	REGISTRY
81	RN	115198-38-4	REGISTRY
82	RN	115198-37-3	REGISTRY
83	RN	115198-36-2	REGISTRY
84	RN	115198-35-1	REGISTRY
85	RN	115198-34-0	REGISTRY
86	RN	115198-33-9	REGISTRY
87	RN	115198-32-8	REGISTRY
88	RN	115198-31-7	REGISTRY
89	RN	115198-30-6	REGISTRY
90	RN	115198-29-3	REGISTRY
91	RN	115198-28-2	REGISTRY
92	RN	115198-27-1	REGISTRY
93	RN	115198-26-0	REGISTRY
94	RN	115198-25-9	REGISTRY
95	RN	114799-60-9	REGISTRY
96	RN	114787-47-2	REGISTRY
97	RN	114773-12-5	REGISTRY
98	RN	103545-15-9	REGISTRY
99	RN	102106-41-2	REGISTRY
100	RN	100982-50-1	REGISTRY
101	RN	91221-46-4	REGISTRY
102	RN	82413-20-5	REGISTRY
103	RN	68684-63-9	REGISTRY
104	RN	56287-31-1	REGISTRY
105	RN	54965-24-1	REGISTRY
106	RN	53005-05-3	REGISTRY
107	RN	51023-76-8	REGISTRY
108	RN	15690-57-0	REGISTRY
DR	96189-16-1		
109	RN	15690-55-8	REGISTRY


110 RN 10540-29-1 REGISTRY  
 111 RN 10448-84-7 REGISTRY  
 DR 35258-22-1  
 112 RN 5863-35-4 REGISTRY  
 DR 11126-33-3, 28794-69-6  
 113 RN 911-45-5 REGISTRY  
 114 RN 569-57-3 REGISTRY  
 DR 13003-83-3  
 115 RN 522-40-7 REGISTRY  
 DR 43049-99-6  
 116 RN 495-99-8 REGISTRY  
 117 RN 316-23-4 REGISTRY  
 118 RN 56-53-1 REGISTRY  
 DR 8026-45-7, 8028-09-9, 8030-34-0, 8049-42-1, 8053-00-7  
 119 RN 50-41-9 REGISTRY

=&gt;

=&gt;


=> d ide can 120 1 9 13 16 52 54 56 58 59 60 61 62 64 95 96 97 98 99 100 101 102  
 103 104 105 106 107 108 110 111 112 113 114 115 116 117 118 119

L20 ANSWER 1 OF 119 REGISTRY COPYRIGHT 2001 ACS  
 RN 209684-38-8 REGISTRY  
 CN Phenol, 3-[1-[4-[2-[ethyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-  
 butenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA  
 INDEX NAME)  
 MF C33 H35 N O2 . C6 H8 O7  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL  
  
 CM 1  
  
 CRN 209684-24-2  
 CMF C33 H35 N O2



CM 2


CRN 77-92-9  
 CMF C6 H8 O7



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:100036

L20 ANSWER 9 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 165813-04-7 REGISTRY  
CN Phenol, 3-[1-[4-[2-(ethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI)  
(CA INDEX NAME)  
FS 3D CONCORD  
MF C26 H29 N O2  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:100036

REFERENCE 2: 123:93335


L20 ANSWER 13 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 147323-04-4 REGISTRY  
CN Benzaldehyde, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C27 H29 N O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532


L20 ANSWER 16 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 147322-99-4 REGISTRY  
CN Oxirane, [[4-(1,2-diphenyl-1-butenyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C25 H24 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

L20 ANSWER 52 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 147308-13-2 REGISTRY  
CN Phenol, 4-(1,2-diphenyl-1-butenyl)-, potassium salt (9CI) (CA INDEX NAME)  
MF C22 H20 O . K  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER  
CRN (68684-63-9)




● K

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

L20 ANSWER 54 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 128068-59-7 REGISTRY  
CN 4H-Thiazolo[5,4-b]azepine, 2-(1,2-diphenylethenyl)-5,6,7,8-tetrahydro-,  
monohydrochloride (9CI) (CA INDEX NAME)  
MF C21 H20 N2 S . Cl H  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




● HCl

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 116:83664

REFERENCE 2: 113:40664

L20 ANSWER 56 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 124499-28-1 REGISTRY  
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-(2-phenylethenyl)phenyl]ethyl]- (9CI)  
(CA INDEX NAME)  
FS 3D CONCORD  
MF C24 H19 N O2  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, USPATFULL  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 115:136564

REFERENCE 2: 112:119353

L20 ANSWER 58 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN **124498-89-1** REGISTRY  
CN Adenosine, 2-[[2-[4-(2-phenylethenyl)phenyl]ethyl]amino]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C26 H28 N6 O4  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 115:136564

REFERENCE 2: 112:119353

L20 ANSWER 59 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN **119809-77-7** REGISTRY  
CN Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1-oxo-2,3-diphenyl-2-propenyl)- (9CI) (CA INDEX NAME)  
MF C29 H29 N5 O3

SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:90313

REFERENCE 2: 110:154320

L20 ANSWER 60 OF 119 REGISTRY .COPYRIGHT 2001 ACS

RN 116057-75-1 REGISTRY

CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pyrrolidine, 1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]-, (E)-

OTHER NAMES:

CN CB 7432

CN Idoxifene

CN SB 223030


FS STEREOSEARCH

MF C28 H30 I N O

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL  
(\*File contains numerically searchable property data)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

99 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
100 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:205530  
REFERENCE 2: 135:205490  
REFERENCE 3: 135:142233  
REFERENCE 4: 135:132470  
REFERENCE 5: 135:116436  
REFERENCE 6: 135:86677  
REFERENCE 7: 135:82051  
REFERENCE 8: 135:71210  
REFERENCE 9: 135:71043  
REFERENCE 10: 135:55767

L20 ANSWER 61 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 115466-00-7 REGISTRY

CN Benzeneethanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-.alpha.-methyl-2-(2-phenylethenyl)-, (E)-, (2E)-2-butenedioate (3:5) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN Benzeneethanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-.alpha.-methyl-2-(2-phenylethenyl)-, (E)-, (E)-2-butenedioate (3:5)

FS STEREOSEARCH  
MF C28 H33 N O3 . 5/3 C4 H4 O4  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 115198-40-8  
CMF C28 H33 N O3


Double bond geometry as shown.



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:54470

L20 ANSWER 62 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 115216-67-6 REGISTRY  
CN Benzenepropanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-N,.alpha.-dimethyl-2-(2-phenylethenyl)-, hydrochloride, (E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C30 H37 N O3 . C1 H  
SR CA  
LC STN Files: CA, CAPLUS  
CRN (115216-66-5)

Double bond geometry as shown.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:54470

L20 ANSWER 64 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 115198-55-5 REGISTRY  
CN 1-Naphthaleneethanamine, N-[2-[2-[(2E)-2-(4-fluorophenyl)ethenyl]-5-methoxyphenyl]-1-methylethyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Naphthaleneethanamine, N-[2-[2-[2-(4-fluorophenyl)ethenyl]-5-methoxyphenyl]-1-methylethyl]-, (E)-, (E)-2-butenedioate (2:1)  
FS STEREOSEARCH

MF C30 H30 F N O . 1/2 C4 H4 O4

SR CA


LC STN Files: CA, CAPLUS

CM 1

CRN 115198-44-2

CMF C30 H30 F N O


Double bond geometry as shown.



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:54470

L20 ANSWER 95 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 114799-60-9 REGISTRY  
CN Benzoic acid, 2-[2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C24 H25 Cl N2 O3  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, TOXLIT, USPATFULL  
(\*File contains numerically searchable property data)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:191374

REFERENCE 2: 109:129008

L20 ANSWER 96 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 114787-47-2 REGISTRY  
CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-5-(1-oxo-2,3-diphenyl-2-propenyl)-1-(phenylmethyl)-, [S-(E)]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C29 H25 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.  
Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:73432

L20 ANSWER 97 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 114773-12-5 REGISTRY  
CN Benzonitrile, 2-[2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C24 H24 Cl N3 O  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, TOXLIT, USPATFULL  
(\*File contains numerically searchable property data)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:191374

REFERENCE 2: 109:129008

L20 ANSWER 98 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN 103545-15-9 REGISTRY  
CN 2-Propanol, 1-(dimethylamino)-3-[4-(1,2-diphenyl-1-butenyl)phenoxy]- (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN ICI 94230

FS 3D CONCORD  
 MF C27 H31 N O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


3 REFERENCES IN FILE CA (1967 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

REFERENCE 2: 107:109578

REFERENCE 3: 105:72884

L20 ANSWER 99 OF 119 REGISTRY COPYRIGHT 2001 ACS  
 RN 102106-41-2 REGISTRY  
 CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-  
 , 2,3-diphenyl-2-propenyl methyl ester (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C31 H28 N2 O6  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 104:207168

L20 ANSWER 100 OF 119 REGISTRY COPYRIGHT 2001 ACS  
 RN 100982-50-1 REGISTRY  
 CN Piperazine, 1-(2,3-diphenyl-2-propenyl)-4-(3-pyridinylmethyl)- (9CI) (CA

INDEX NAME)  
 FS 3D CONCORD  
 MF C25 H27 N3  
 SR CA  
 LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 104:129927

L20 ANSWER 101 OF 119 REGISTRY COPYRIGHT 2001 ACS  
 RN 91221-46-4 REGISTRY  
 CN Phenol, 4,4'-(2-phenyl-1-butenylidene)bis- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H20 O2  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CANCERLIT, CAPLUS, CASREACT, DDFU, DRUGU,  
 MEDLINE, TOXLIT  
 (\*File contains numerically searchable property data).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 9 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

REFERENCE 2: 114:74630  
REFERENCE 3: 108:198542  
REFERENCE 4: 108:74905  
REFERENCE 5: 107:146821  
REFERENCE 6: 107:96423  
REFERENCE 7: 106:116021  
REFERENCE 8: 106:44227  
REFERENCE 9: 101:72346

L20 ANSWER 102 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 82413-20-5 REGISTRY

CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-  
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-,  
(E)-

OTHER NAMES:

CN 3-Hydroxytamoxifen

CN Droloxifene

CN E-Droloxifene

CN K 060

CN K 060E

CN K 21.060E

FS STEREOSEARCH


MF C26 H29 N O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,  
CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE,  
MRCK\*, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXLIT, ULIDAT, USAN, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

171 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
171 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:267223  
REFERENCE 2: 135:205530  
REFERENCE 3: 135:132470  
REFERENCE 4: 135:117261  
REFERENCE 5: 135:76700  
REFERENCE 6: 135:71241  
REFERENCE 7: 135:14359  
REFERENCE 8: 134:348291  
REFERENCE 9: 134:305328  
REFERENCE 10: 134:305076

L20 ANSWER 103 OF 119 REGISTRY COPYRIGHT 2001 ACS  
RN **68684-63-9** REGISTRY  
CN Phenol, 4-(1,2-diphenyl-1-butenyl)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 4-(1,2-Diphenylbut-1-enyl)phenol  
CN ICI 77949  
FS 3D CONCORD  
MF C22 H20 O  
CI COM  
LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS,  
CASREACT, DDFU, DRUGU, EMBASE, MEDLINE, TOXLIT, USPATFULL  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

12 REFERENCES IN FILE CA (1967 TO DATE)  
12 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:282668  
REFERENCE 2: 126:157285  
REFERENCE 3: 125:292411

REFERENCE 4: 118:254532  
 REFERENCE 5: 112:69490  
 REFERENCE 6: 108:186248  
 REFERENCE 7: 103:17049  
 REFERENCE 8: 102:215475  
 REFERENCE 9: 102:672  
 REFERENCE 10: 99:641

L20 ANSWER 104 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 56287-31-1 REGISTRY

CN 1-Propanamine, 3-[4-[1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]-  
 N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA  
 INDEX NAME)

OTHER NAMES:

CN CI 680


MF C26 H28 N2 O4 . C6 H8 O7

LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, DDFU, DRUGU,  
 EMBASE, MEDLINE, TOXLIT, USPATFULL  
 (\*File contains numerically searchable property data)

CM 1

CRN 56287-30-0


CMF C26 H28 N2 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7



15 REFERENCES IN FILE CA (1967 TO DATE)

15 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:86015  
REFERENCE 2: 129:86008  
REFERENCE 3: 129:67926  
REFERENCE 4: 116:144146  
REFERENCE 5: 113:561  
REFERENCE 6: 105:72688  
REFERENCE 7: 100:185961  
REFERENCE 8: 100:96934  
REFERENCE 9: 97:1031  
REFERENCE 10: 96:80182

L20 ANSWER 105 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 54965-24-1 REGISTRY

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-,  
2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-,  
2-hydroxy-1,2,3-propanetricarboxylate (1:1)

OTHER NAMES:

CN ICI 46474

CN Nolvadex

CN Tamoplex

CN Tamox-Puren

CN Tamoxifen citrate

CN Z-Tamoxifen citrate

FS STEREOSEARCH

MF C26 H29 N O . C6 H8 O7

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,  
DIOGENES, DRUGPAT, EMBASE, HSDB\*, IPA, MRCK\*, MSDS-OHS, PHARMASEARCH,  
PIRA, PROMT, RTECS\*, TOXLIT, ULIDAT, USAN, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*


(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 10540-29-1

CMF C26 H29 N O


Double bond geometry as shown.



CM 2

CRN 77-92-9

CMF C6 H8 O7



180 REFERENCES IN FILE CA (1967 TO DATE)

180 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:252083  
 REFERENCE 2: 135:205083  
 REFERENCE 3: 135:174425  
 REFERENCE 4: 135:71266  
 REFERENCE 5: 134:371761  
 REFERENCE 6: 134:173196  
 REFERENCE 7: 134:66360  
 REFERENCE 8: 134:32972  
 REFERENCE 9: 133:359224  
 REFERENCE 10: 133:340231

L20 ANSWER 106 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 53005-05-3 REGISTRY

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-isothiocyanato- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN 4,4'-Diisothiocyanato-2,2'-stilbenedisulfonic acid

CN DIDS

FS 3D CONCORD


MF C16 H10 N2 O6 S4

CI COM

LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS,  
CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NIOSHTIC, PIRA,

TOXLIT, USPATFULL

(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

527 REFERENCES IN FILE CA (1967 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

527 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:314438

REFERENCE 2: 135:301293

REFERENCE 3: 135:299709

REFERENCE 4: 135:298460

REFERENCE 5: 135:298121

REFERENCE 6: 135:271097

REFERENCE 7: 135:237995

REFERENCE 8: 135:207895

REFERENCE 9: 135:118359

REFERENCE 10: 135:102474

L20 ANSWER 107 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 51023-76-8 REGISTRY

CN Benzenesulfonic acid, 5-(acetamino)-2-[2-(4-isothiocyanto-2-sulfohenyl)ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Disodium 4-acetamido-4'-isothiocyantostilbene-2,2'-disulfonate

CN SITS


MF C17 H14 N2 O7 S3 . 2 Na

LC STN Files: ADISINSIGHT, AGRICOLA, BIOBUSINESS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MSDS-OHS, TOXLIT, USPATFULL

Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (27816-59-7)



● 2 Na

146 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 146 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:314438  
 REFERENCE 2: 135:298460  
 REFERENCE 3: 135:31877  
 REFERENCE 4: 134:110420  
 REFERENCE 5: 133:218637  
 REFERENCE 6: 133:114784  
 REFERENCE 7: 133:13989  
 REFERENCE 8: 133:12415  
 REFERENCE 9: 132:305946  
 REFERENCE 10: 131:297859

L20 ANSWER 108 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 15690-57-0 REGISTRY

CN Ethanamine, 2-[4-[(1E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethyl-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-, (E)-  
 CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, (E)- (8CI)

OTHER NAMES:

CN (E)-Clomiphene

CN 2-[p-(2-Chloro-trans-1,2-diphenylvinyl)phenoxy]triethylamine

CN Enclomifene

CN Enclomiphene

CN ICI 46476

CN trans-Clomifene

CN trans-Clomiphene

FS STEREOSEARCH

DR 96189-16-1


MF C26 H28 Cl N O

CI COM

LC STN Files: AGRICOLA, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,  
 CAPLUS, CASREACT, CHEMINFORMRX, CHEMLIST, DDFU, DRUGU, EMBASE, IFICDB,  
 IFIPAT, IFIUDB, IPA, RTECS\*, TOXCENTER, TOXLIT, USAN, USPATFULL, VETU

(\*File contains numerically searchable property data)  
Other Sources: WHO

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

123 REFERENCES IN FILE CA (1967 TO DATE)  
123 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:134953  
REFERENCE 2: 134:320982  
REFERENCE 3: 134:285588  
REFERENCE 4: 134:271284  
REFERENCE 5: 131:281723  
REFERENCE 6: 131:252109  
REFERENCE 7: 130:105686  
REFERENCE 8: 130:20130  
REFERENCE 9: 129:339850  
REFERENCE 10: 129:326941

L20 ANSWER 110 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 10540-29-1 REGISTRY

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-

CN Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-  
(8CI)

OTHER NAMES:

CN ICI 47699

CN Mammaton

CN Tamofen

CN Tamoxifen

CN trans-Tamoxifen

CN Z-Tamoxifen

FS STEREOSEARCH

MF C26 H29 N O

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, EMBASE, HSDB\*, IPA, MEDLINE, MRCK\*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS\*, SPECINFO, TOXCENTER, TOXLIT, ULIDAT, USAN, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4094 REFERENCES IN FILE CA (1967 TO DATE)  
118 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
4108 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:316401  
REFERENCE 2: 135:313756  
REFERENCE 3: 135:313606  
REFERENCE 4: 135:313519  
REFERENCE 5: 135:313320  
REFERENCE 6: 135:313271  
REFERENCE 7: 135:313025  
REFERENCE 8: 135:302906  
REFERENCE 9: 135:300662  
REFERENCE 10: 135:298909

L20 ANSWER 111 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 10448-84-7 REGISTRY


CN Pyrrolidine, 1-[2-[4-[1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pyrrolidine, 1-[2-[p-[.alpha.-(p-methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]- (7CI, 8CI)

OTHER NAMES:

CN CN 55945  
 CN Nitromifene  
 FS 3D CONCORD  
 DR 35258-22-1  
 MF C27 H28 N2 O4  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CANCERLIT, CAOLD, CAPLUS, DDFU, DRUGU,  
 MEDLINE, RTECS\*, TOXCENTER, TOXLIT, USAN, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

25 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 25 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:25113  
 REFERENCE 2: 132:217295  
 REFERENCE 3: 132:156868  
 REFERENCE 4: 130:148713  
 REFERENCE 5: 122:305842  
 REFERENCE 6: 114:17699

REFERENCE 7: 113:561

REFERENCE 8: 112:30764

REFERENCE 9: 110:3209

REFERENCE 10: 108:49540

L20 ANSWER 112 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 5863-35-4 REGISTRY

CN Pyrrolidine, 1-[2-[4-[1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pyrrolidine, 1-[2-[p-[.alpha.-(p-methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]-, citrate (7CI)

CN Pyrrolidine, 1-[2-[p-[.alpha.-(p-methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]-, citrate (1:1) (8CI)

OTHER NAMES:

CN 1-[2-(p-[a-(p-Methoxyphenyl)-.beta.-nitrostyryl]-phenoxy)ethyl]pyrrolidine monocitrate

CN 1-[2-[4-[2-(4-Methoxyphenyl)-1-nitro-2-phenylethenyl]phenoxy]ethyl]pyrrolidine monocitrate

CN 1-[2-[p-[.alpha.-(p-Methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]pyrrolidine monocitrate

CN 1-[2-[p-[.alpha.-(p-Methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]pyrrolidine monocitrate

CN CI 628

CN CN 55945-27

CN Nitromifene citrate

CN Parke Davis CI-628

DR 11126-33-3, 28794-69-6


MF C27 H28 N2 O4 . C6 H8 O7

LC STN Files: BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, EMBASE, RTECS\*, TOXLIT, USAN, USPATFULL  
(\*File contains numerically searchable property data)

CM 1

CRN 10448-84-7


CMF C27 H28 N2 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7



190 REFERENCES IN FILE CA (1967 TO DATE)  
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 190 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:29254  
 REFERENCE 2: 130:320985  
 REFERENCE 3: 129:86015  
 REFERENCE 4: 129:86008  
 REFERENCE 5: 129:67926  
 REFERENCE 6: 128:176274  
 REFERENCE 7: 126:195078

REFERENCE 8: 119:109266

REFERENCE 9: 116:853

REFERENCE 10: 115:174956

L20 ANSWER 113 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 911-45-5 REGISTRY

CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl- (9CI)  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]- (7CI, 8CI)

OTHER NAMES:

CN 1-(p-.beta.-Diethylaminoethoxyphenyl)-1,2-diphenyl-2-chloroethylene

CN 2-[p-(.beta.-Chloro-.alpha.-phenylstyryl)phenoxy]triethylamine

CN 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine

CN Clomifene

CN Clomiphene

CN Clomiphene B

FS 3D CONCORD

MF C26 H28 Cl N O


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,  
CHEMINFORMRX, CHEMLIST, CIN, CSCHM, DDFU, DRUGU, EMBASE, HSDB\*, IFICDB,  
IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, NIOSHTIC, PROMT, RTECS\*, SPECINFO,  
TOXLIT, USAN, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

501 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

501 REFERENCES IN FILE CAPLUS (1967 TO DATE)

16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:253084

REFERENCE 2: 135:231505

REFERENCE 3: 135:216008

REFERENCE 4: 135:175656

REFERENCE 5: 135:149615  
 REFERENCE 6: 135:132406  
 REFERENCE 7: 135:132352  
 REFERENCE 8: 135:117331  
 REFERENCE 9: 135:116519  
 REFERENCE 10: 135:102687

L20 ANSWER 114 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 569-57-3 REGISTRY

CN Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Chlorotrianisene (6CI)

CN Ethylene, chlorotris(p-methoxyphenyl)- (7CI, 8CI)


OTHER NAMES:

CN Anisene  
 CN Chlorotris(p-methoxyphenyl)ethylene  
 CN Chlortrianizen  
 CN Clorestrolo  
 CN Clorotrisin  
 CN Hormonisene  
 CN Khlortrianizen  
 CN Merbentul  
 CN Metace  
 CN NSC 10108  
 CN Rianil  
 CN Tace  
 CN Tace (pharmaceutical)  
 CN Tri-p-anisylchloroethylene  
 CN Trianisylchloroethylene  
 CN Tris(p-methoxyphenyl)chloroethylene  
 FS 3D CONCORD  
 DR 13003-83-3  
 MF C23 H21 Cl O3

LC STN Files: ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, .  
 CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN,  
 CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC\*, HSDB\*, IPA, MEDLINE,  
 MRCK\*, NIOSHTIC, PROMT, RTECS\*, SPECINFO, TOXLIT, USAN, USPATFULL  
 (\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

101 REFERENCES IN FILE CA (1967 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 101 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 30 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:288636  
 REFERENCE 2: 135:190550  
 REFERENCE 3: 135:127211  
 REFERENCE 4: 134:33012  
 REFERENCE 5: 133:305586  
 REFERENCE 6: 133:217722  
 REFERENCE 7: 133:129857  
 REFERENCE 8: 133:109949  
 REFERENCE 9: 132:329551  
 REFERENCE 10: 132:156865

L20 ANSWER 115 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 522-40-7 REGISTRY

CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis-, bis(dihydrogen phosphate) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, bis(dihydrogen phosphate), (E)- (8CI)

CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, bis(dihydrogen phosphate), (E)-

OTHER NAMES:

CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol diphosphoric acid ester

CN Diethyldihydroxystilbene diphosphate

CN Diethylstilbestrol diphosphate

CN Diethylstilbestrol diphosphate

CN Diethylstilbestryl diphosphate

CN Fosfestrol

CN Honvan

CN Phosphestrol

CN ST 52-Asta

CN Stilbestrol diphosphate

CN Stilphostrol

FS STEREOSEARCH

DR 43049-99-6

MF C18 H22 O8 P2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IPA, MRCK\*, NIOSHTIC, PHARMASEARCH, PROMT, RTECS\*, TOXLIT, USAN, USPATFULL  
 (\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

138 REFERENCES IN FILE CA (1967 TO DATE)  
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 138 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:33012  
 REFERENCE 2: 132:73826  
 REFERENCE 3: 131:346535  
 REFERENCE 4: 131:194509  
 REFERENCE 5: 131:156287  
 REFERENCE 6: 131:35892  
 REFERENCE 7: 131:23554  
 REFERENCE 8: 131:23553  
 REFERENCE 9: 130:108397  
 REFERENCE 10: 130:482

L20 ANSWER 116 OF 119 REGISTRY COPYRIGHT 2001 ACS  
 RN 495-99-8 REGISTRY  
 CN Benzenecarboximidamide, 4-[2-[4-(aminoiminomethyl)phenyl]ethenyl]-3-hydroxy- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 4,4'-Stilbenedicarboxamidine, 2-hydroxy- (7CI, 8CI)  
 OTHER NAMES:  
 CN 2-Hydroxy-4,4'-stilbenedicarboxamidine  
 CN Hydroxystilbamidine  
 CN OHS  
 FS 3D CONCORD  
 MF C16 H16 N4 O  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CEN, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, MEDLINE, MRCK\*, PIRA, RTECS\*, SPECINFO, TOXLIT, USAN, USPATFULL

(\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

41 REFERENCES IN FILE CA (1967 TO DATE)  
 41 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:24675  
 REFERENCE 2: 135:114  
 REFERENCE 3: 132:339430  
 REFERENCE 4: 124:44887  
 REFERENCE 5: 116:37120  
 REFERENCE 6: 115:227445  
 REFERENCE 7: 110:162889  
 REFERENCE 8: 105:205223  
 REFERENCE 9: 105:17878  
 REFERENCE 10: 104:141770

L20 ANSWER 117 OF 119 REGISTRY COPYRIGHT 2001 ACS  
 RN 316-23-4 REGISTRY

CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, bis(hydrogen sulfate), (E)-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, bis(hydrogen sulfate), (E)-  
 (8CI)

OTHER NAMES:

CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol disulfuric acid ester, (E)-  
 CN Diethylstilbestrol 4,4'-disulfuric ester  
 CN Diethylstilbestrol disulfate  
 CN Diethylstilbestryl disulfate  
 CN Stilbestrol disulfate  
 FS STEREOSEARCH  
 MF C18 H20 O8 S2  
 CI COM  
 LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, CHEMLIST, TOXLIT  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7 REFERENCES IN FILE CA (1967 TO DATE)  
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 90:16821  
REFERENCE 2: 83:126645  
REFERENCE 3: 79:122020  
REFERENCE 4: 76:81403  
REFERENCE 5: 72:392  
REFERENCE 6: 70:84604  
REFERENCE 7: 70:17363

L20 ANSWER 118 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 56-53-1 REGISTRY

CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, (E)- (8CI)

CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-

OTHER NAMES:


CN (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene  
CN (E)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol  
CN (E)-Diethylstilbestrol  
CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol  
CN .alpha.,.alpha.'-Diethylstilbenediol  
CN 4,4'-Dihydroxy-.alpha.,.beta.-diethylstilbene  
CN 4,4'-Dihydroxydiethylstilbene  
CN Agostilben  
CN Antigestil  
CN Bio-des  
CN Bufon  
CN Comestrol  
CN Cyren  
CN Cyren A  
CN Dawe's destrol  
CN DEB  
CN DES  
CN DES (synthetic estrogen)

CN Di-Estryl  
 CN DiBestrol 2 Premix  
 CN Diethylstilbestrol  
 CN Distilbene  
 CN Domestrol  
 CN Estilbin MCO  
 CN Estrobene  
 CN Estromenin  
 CN Estrosyn  
 CN Fonatol  
 CN Grafestrol  
 CN Hi-Bestrol  
 CN Iscovesco  
 CN Menostilbeen  
 CN Microest  
 CN Milestrol  
 CN Neo-Oestranol I  
 CN Oestrogenine  
 CN Oestromenin  
 CN Oestromensyl  
 CN Pabestrol  
 CN Palestrol  
 CN Rumestrol 1  
 CN Rumestrol 2  
 CN Serral  
 CN Sexocretin  
 CN Sibol  
 CN Stil  
 CN Stil-Rol  
 CN Stilbestrol

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

FS STEREOSEARCH  
 DR 8026-45-7, 8028-09-9, 8030-34-0, 8049-42-1, 8053-00-7  
 MF C18 H20 O2  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,  
 CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM\*, DIOGENES, DRUGU,  
 EMBASE, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*,  
 MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS\*, SPECINFO, TOXLIT, ULIDAT, USAN,  
 USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4816 REFERENCES IN FILE CA (1967 TO DATE)  
 91 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 4821 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 35 REFERENCES IN FILE CAOLD (PRIOR TO 1967) .

REFERENCE 1: 135:314622  
 REFERENCE 2: 135:313797  
 REFERENCE 3: 135:313320  
 REFERENCE 4: 135:303215  
 REFERENCE 5: 135:299875  
 REFERENCE 6: 135:288636  
 REFERENCE 7: 135:288504  
 REFERENCE 8: 135:286909  
 REFERENCE 9: 135:284382  
 REFERENCE 10: 135:284251

L20 ANSWER 119 OF 119 REGISTRY COPYRIGHT 2001 ACS

RN 50-41-9 REGISTRY

CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-,  
 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (6CI,  
 7CI)

CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (1:1)  
 (8CI)


OTHER NAMES:

CN 1-[p-(.beta.-Diethylaminoethoxy)phenyl]-1,2-diphenyl-2-chloroethylene  
 citrate  
 CN 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine dihydrogen citrate  
 CN Chloramiphen  
 CN Clomid  
 CN Clomifene citrate  
 CN Clomifeno  
 CN Clomiphene citrate  
 CN Clomiphene dihydrogen citrate  
 CN Clomivid  
 CN Clomphid  
 CN Clostilbegyt  
 CN Dyneric  
 CN Fertivet  
 CN Fertyl  
 CN Genozym  
 CN Ikaclomin  
 CN Mer 41  
 CN MRL 41  
 CN Omifin  
 CN Racemic clomiphene citrate  
 MF C26 H28 Cl N O . C6 H8 O7

CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,  
 DIOGENES, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK\*, MSDS-OHS,  
 NIOSHTIC, PHARMASEARCH, PROMT, RTECS\*, TOXLIT, USAN, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)


CM 1

CRN 911-45-5  
 CMF C26 H28 Cl N O



CM 2

CRN 77-92-9  
 CMF C6 H8 O7



644 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 646 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:268418  
 REFERENCE 2: 135:267389  
 REFERENCE 3: 135:221503  
 REFERENCE 4: 135:221432  
 REFERENCE 5: 135:221411  
 REFERENCE 6: 135:205651  
 REFERENCE 7: 135:116199  
 REFERENCE 8: 135:71383

Tate 09\_890416

REFERENCE 9: 134:290552

REFERENCE 10: 134:285588